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The occurrence of pharmaceuticals in wastewater and the wider environment is of 
growing concern. This thesis focuses on anticancer drugs - a group of biologically-
potent and often recalcitrant set of chemicals whose fate and impact on the wider 
freshwater environment is poorly studied. The aims of this thesis were to prioritise a 
group of anticancer drugs for environmental monitoring programmes (from the many 
drugs in use), based on their consumption and fate during wastewater treatment; to 
undertake a national and regional survey of two commonly used anticancer drugs, 
cyclophosphamide (CP) and ifosfamide (IF) in wastewater and river water; to assess 
the performance of a river-based chemical fate model through comparisons with field 
observations; and to conduct a mass balance for CP in wastewater treatment plants to 
assess chemical fate during the different stages of wastewater treatment. 
Given the large number of anticancer drugs currently in use (>70) a decision support 
process was developed to ascertain a short list of drugs which are most likely to 
persist and be released with treated effluent to environmental waters. To do this, 
accurate consumption data were compiled from a hospital survey in NW England and 
combined with urinary excretion rates derived from clinical studies. Physical–
chemical property data were then compiled along with likely chemical fate and 
persistence during and after wastewater treatment. A shortlist of 15 chemicals (from 
65), including CP and IF, was prioritised based on their consumption, persistency and 
likelihood of occurrence in surface waters and supported by observational studies 
where possible. The ecological impact of these ‘prioritised’ chemicals however is 
uncertain as the measured concentrations in surface waters generally fall below 
standard toxicity thresholds, although there is evidence that exposure of aquatic 
organisms to some of these chemicals may induce low-dose genotoxic effects. This 
prioritised sub-list of anticancer drugs should prove useful for developing 
environmental screening programmes and targeted toxicity assays.
To assess the occurrence of anticancer drugs in wasterwaters both CP and IF were 
measured in raw influent and final effluent waters from fourteen STPs located across 
England using a sensitive analytical method. CP was detected in both wastewater 
influent and effluent with mean (SD) concentration of 4.1 ng/L (4.8) and 6.6 ng/L 
(6.5), respectively, in agreement to measured ranges from a limited number of studies 
conducted in Europe and elsewhere. IF was only detected in four wastewater samples 
with the highest concentration being observed in wastewater effluent at 0.77 ng/L (cv 
= 24.3% (n=3)) and possibly reflecting the relatively lower consumption of this drug 
relative to CP. Additional monitoring was conducted in the rivers Calder, Darwen and 
Ribble (North West UK) with CP present at 5 of the 6 river locations with 
concentrations ranging from 0.41 to 3.71 ng/L. All these rivers receive treated 
wastewater effluent from sewage treatment works serving different population sizes, 
with CP measured in river water some ~20 miles downstream of the nearest STP, 
indicating the widespread dispersal and persistence of this chemical. 
CP and IF were measured systematically down the Rivers Aire and Calder in NE 
England and the results compared to a GIS-based water quality model (LF2000-
WQX) used to predict CP and IF distributions in the two rivers, using regional 
consumption data and subsequent release quantities from STPs. CP was detected in 90 
iii 
% of river samples, apart from rural/uplands sites located at the source of the River 
Aire and Calder, respectively. CP presented the highest concentration, ranging from 
0.17 to 4.53 ng/L (average 1.14 ng/L). IF was seldom detected in the sampled sites 
and concentrations ranged from < LOD to 1.82 ng/L (average 0.51 ng/L). Model 
results showed a fair agreement to the measured data for CP in the River Aire, 
discrepancies arise as the river progressed further downstream where the modelled 
data was lower than the measured data. A significant input of CP from Leeds STP at 
A7 (STP-1) saw the continuing rise in CP despite the increase in river flow. At the 
lower end of the Calder (pre-confluence with the River Aire) a spike in CP is detected 
far beyond the modelled value. A risk assessment was carried out to establish the 
potential adverse effects of anticancer drugs in the river catchment. All calculated risk 
quotients were below 1, showing no significant risk to aquatic organisms. However, 
long term toxicity studies for these chemicals are needed to define the environmental 
stress produced by their continuous exposure and induction.  
The fate and removal efficiency of cyclophosphamide (CP) and ifosfamide (IF) were 
investigated in two conventional sewage treatment plants (STP-S and STP-C) during 
different stages of waste water treatment. Overall average concentrations of CP were 
1.17±1 ng/L in the two plants, which is lower than recent measurements conducted 
elsewhere. Grab-samples were coordinated with the hydraulic residence time of 
wastewater in each of the treatment stages in order to monitor changes in CP 
concentrations in the same parcel of water as it passed through the STP. Interestingly, 
concentrations of CP were observed to increase from raw influent to final tertiary-
treated effluent and this is likely to be attributable to the degradation of a CP-
metabolite and subsequent ‘liberation’ of the parent CP as the metabolite passes 
through the various sewage treatment processes. This observation, apparent in both 
studied STPs, has implications for chemical fate modelling of anti-cancer drugs, 
especially if STP influent loads are used to predict subsequent fluxes to receiving 
waters rather than final effluent values. Moreover, this increase in concentrations 
made a mass balance difficult to achieve, but highlighted that elimination/removal of 
CP in wastewater during primary to tertiary processing is very low (<20%). The 
calculated fluxes of CP with final effluent discharge were 3.16- 6.48 g/year for STP-S 
and 4.56 -51.57 g/year for STP-C and highlight that STPs are a continuing source of 
highly water-soluble, recalcitrant anticancer drugs to the environment.  
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This thesis investigates the environmental occurrence of a specific group of 
pharmaceuticals - anticancer drugs –with a growing number of studies showing their 
occurrence in sewage wastewaters and receiving waters (Yin et al., 2010, Kümmerer 
et al., 1997, Buerge et al., 2006, Garcia-Ac et al., 2009, Martín et al., 2011, Coetsier et 
al., 2009, Zuccato et al., 2000, Valcárcel et al., 2011).  Over the last 15 years there has 
been a rise in the number of scientific papers examining the occurrence of 
pharmaceuticals in waste water systems, with concern about the impact of these 
chemicals on the aquatic environment and risk to human health through consumption 
with drinking water (Johnson et al., 2008, Booker et al., 2014, Besse et al., 2012). 
Anticancer drugs represent a toxicologically potent group of chemicals given that 
some of these compounds are designed to be genotoxic and can accelerate cell 
apoptosis. The potential longevity of these chemicals and their resistance to 
breakdown during wastewater treatment processes is therefore of concern and 
warrants research into their environmental occurrence, behaviour and impact. This 
initial chapter serves as the basis for the significance and rationale of the papers 
included in the thesis and the work conducted over the past three years. By definition, 
anticancer drugs are cytotoxic in action are continually released through 
hospital/municipal wastewaters, and as such have been increasingly reported in the 
environment as analytical methodologies have been developed or improved 
(Llewellyn et al., 2011, Buerge et al., 2006, Castiglioni et al., 2005, Moldovan, 2006). 
Major rivers such as the River Thames in SE England receive a wide array of 
pharmaceuticals from the large number of STPs that discharge to the river (Rowney et 
al., 2009). As river water is abstracted for drinking water then risks to human health 
through exposure to very low doses of these chemicals has to be assessed. At present 
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pharmaceuticals are not legislated for in wastewater effluents or receiving waters due 
to the lack of observational studies and knowledge about their fate and impact. These 
chemicals are not currently included in priority lists of hazardous substances in the 
EU’s Water Framework Directive (EU Water Framework Directive (no date)). 
Furthermore, negative aspects associated with the risk they pose to the wider 
environment needs to be balanced with their overriding beneficial use in the treatment 
of cancers through chemotherapy.  
This chapter details the physical and chemical properties of the anticancer drugs 
investigated, their sources and predicted fate in the environment. Their release and 
pathways into the environment is described. There are still many uncertainties 
regarding the ultimate fate of these pollutants in the environment. Their occurrence in 
drinking water is uncertain due to the limitations of the analytical method for this 
challenging group of chemicals and lack of observational/monitoring studies. The 
chapters in this thesis go some way to explaining the behaviour of this class of 
pharmaceutical in wastewater and river water and the processes affecting their fate.  
1.1. Aims and Objectives 
The overarching aim of this thesis is to investigate the occurrence of anticancer drugs 
in the aquatic environment in order to verify their sources and quantify their release 
from sewage treatment plants and occurrence in receiving waters. This will be 
achieved by the following objectives: 
1. To prioritise commonly used anticancer drugs for environmental screening
purposes by critically reviewing their consumption, metabolism rates,
physical-chemical properties and degradation pathways in the environment.
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2. Conduct a nation-wide survey of two commonly used anticancer drugs in
sewage treatment plant influent and effluent wastewaters to acquire measured
environmental concentrations (MEC).
3. Conduct a mass balance tracking the fate of a commonly used anticancer drug
in sewage treatment plants to assess the chemical behaviour and loss between
key wastewater treatment processes.
4. To investigate anticancer drugs in a well characterised river basin in the North
East (NE) England to determine concentrations in river water and test a
catchment ‘low-flow’ chemical fate model for anticancer drugs.
1.2.  Thesis structure 
This thesis is based around four key manuscripts that represent the core of the 
research work and address the objectives listed above. Chapter 2 introduces 
widespread occurrence of pharmaceuticals and personal care products in the 
environment utilizing the literature to present the relevant historical and scientific 
context necessary to understand the context to the research covered in this thesis. 
Chapter 3 discusses the current knowledge on the two key anticancer drugs that were 
the focus for the field and laboratory work conducted in this thesis. The analytical 
methods, including laboratory protocols and instrumentation, as well as the challenges 
arising from these methods, are discussed in chapter 4. The scientific papers that 
comprise the core of this thesis are located in chapter 5, followed by the conclusions 
and recommendations for further research in chapter 6. The papers included in chapter 
5 are: 
I. Prioritisation of anticancer drugs consumed within the North West (NW)
England from a detailed hospital survey. Priority list finalised by
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evaluating the PECs of each anticancer drug with regards to their physical 
chemical profile and likely environmental fate.  
II. Nationwide survey of cyclophosphamide and ifosfamide in fourteen
sewage treatment plants operating different types of treatment, within a
regional river basin study in the NW England.
III. Mass balance of cyclophosphamide and ifosfamide conducted in two
sewage treatment plants in NW England to investigate the reactivation of
cyclophosphamide.
IV. A detailed river basin study in NE England with MECs and PECs for
cyclophosphamide and ifosfamide.
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2. Pharmaceuticals and personal care products
2.1. Definitions and classifications 
A pharmaceutical is defined by EU law as ‘any substance or combination of 
substances presented as having properties for treating or preventing disease in human 
beings’ (European commission enterprise (no date)). Medical advances have led to an 
increasing demand and rising number of agents available in pharmacotherapy. The 
Anatomical Therapeutic Chemical Classification System (ATC system) is a widely 
used classification system for pharmaceutical agents, categorised by mode of action in 
a five tiered system. The first two tiers of the ATC are shown in Table 2.1, 
demonstrating the widespread application and number of different agents obtainable 
in hospitals, general practitioners (GPs), pharmacies and supermarkets.    
Table 2.1: A list of pharmaceutical classes and their applications according to the 
ATC system, tiers 1 and 2   
Code Content 
A Alimentary tract 
and metabolism 
A01-stomatological, A02-acid related disorders, A03-
gastrointestinal, A04-antiemetics and antinauseants, 
A05-bile and liver therapy, A06-constipation, A07-
antidiarrheals, intestinal anti-inflammatory agents, 
A08-antiobesity, A09-digestives, A10-diabetes, A11-
vitamins, A12-minerals, A13-tonics, A14-anabolic 
agents, A15-appetite stimulants, A16-other 
B Blood and blood 
forming organs 
B01-antithrombotic agents, B02-antihemorrhagics, 




C01-cardiac therapy, C02-antihypertensives, C03-
diuretics, C04-peripheral vasodilators, C05-
vasoprotectives, C07-beta blocking agents, C08-
calcium channel blockers, C09-renin-angiotensin 
system, C10-lipid modifying agents 
D Dermatologicals D01-antifungals, D02-Emollients, D03-treatment of 
wounds and ulcers, D04-antipruritics, D05-
antipsoriatics, D06-antibiotics and 
chemotherapeutics, D07-corticosteroids, D08-
antiseptics and disinfectants, D09-medicated 
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dressings, D10-anti-acne, D11-other 
G Genito-urinary 
system and sex 
hormones 
G01-gynecological antiinfectives and antiseptics, 
G02-other gynecologicals, G03-Sex hormones, G04-
urologicals  





H01-pituitary and hypothalamic hormones, H02-
corticosteroids, H03-thyroid, H04-pancreatic, H05-
calcium homeostasis 
J Anti-infective for 
systemic use 
J01-antibacterials, J02-antimycotics, J04-
antimycobacterials, J05-antivirals, J06-immune sera 
and immunoglobulin’s, J07-vaccines 
L Antineoplastic and 
immunomodulating 
agents 




M01-anti-inflammatory, M02-topical products, M03-
muscle relaxants, M04-antigout, M05-drugs for bone 
disease, M09-other 
N Nervous system N01-anesthetics, N02-analgesics, N03-antiepileptics, 








R Respiratory system R01-nasel preparations, R02-throat preparations, 
R03-obstructive airway diseases, R05-cough and 
cold, R06-antihistamines, R07-other 
S Sensory organs S01-ophthalmologicals, S02-otologicals, S03-
Ophthalmological and otological preparations 
V Various V01-allergens, V03-other therapeutic, V04-diagnostic 
agents, V06-general nutrients, V07-other non-
therapeutic, V08-contrast media, V09-diagnostic 
radiopharmaceuticals, V10-therapeutic 
radiopharmaceuticals, V20-surgical dressings 
2.2. History and usage 
Historically, pharmaceuticals were distributed by small scale apothecaries in the 17th 
century that discovered drugs through identifying the active ingredient from 
traditional remedies or by unexpected discovery. In the 19th century, apothecaries 
started wholesale production of drugs such as morphine and quinine. In the late 19th 
century, dye and chemical companies started pharmaceutical production through 
medical applications found in their products.  
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The next progression in pharmaceutical growth was in the earlier 20th century, when 
Paul Ehrlich focused research by postulating that agents (i.e. dyes) would react with 
disease causing organisms (Ehrlich, 1877). Breakthroughs in the development of 
synthetic vitamins, sulphonamides, antibiotics, hormones, psychotropics, 
antihistamines and new vaccines progressed from 1930 to 1960, during this period 
research focus changed to synthetic chemistry (Dowling, 1972, Tobbell, 2008). It was 
the discovery of antimicrobials that gave rise to the high profits in pharmaceutical 
companies, resulting in their expansion. Safety regulations were introduced in 1938 in 
the U.S. after sulfanilamide (an antibiotic) was developed from diethylene glycol and 
caused death to more than 100 people by ingestion of the elixir. The drug was almost 
wholly excreted in the urine, however for patients with poor renal function a 
diminished ability to excrete sulfanilamide resulted in an accumulation of this 
chemical in the body (Kanthak and Pickering). In England, in 1956, a revision of the 
Therapeutic Substances Act was ruled to bring more substances under government 
control and set formal standards for the testing and manufacturing of pharmaceuticals. 
During the past two decades, the pharmaceutical industry has brought a new wave of 
medicines to market, such as drugs for viral and retroviral infection and drugs to cure 
or delay the onslaught of cancer. This had led to the rise of pharmaceuticals with 
between 50,000 and 100,000 being commercially manufactured by industry (2006).  
2.3. Administration 
The administration of a pharmaceuticals to a patient include intravenous, oral or by 
other means of administration such as, intranasal, topical, inhalation and rectal.  
2.4. Environmental occurrence and risk assessments  
Pharmaceuticals are often viewed as ‘emerging contaminants’ in the aquatic 
environment, where they are released in some water bodies and display a subsequent 
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threat to aquatic ecosystems. Pharmaceuticals indirectly enter the environment via 
wastewaters (i.e. hospital, domestic and industrial) through the excretion of the non-
metabolised drug following administration to patients’. The pollution to waterways 
and soils is not only associated with STPs, veterinary medicines enter the 
environment primarily through runoff from manure treated farmlands (Kim et al., 
2008). The water framework directive sets out strategies against the pollution of water 
by prioritising a list of pharmaceuticals that present a significant risk to the aquatic 
environment. The sewage treatment plants (STPs) receiving the wastewaters are not 
designed to remove these micropollutants and since some compounds are not fully 
eliminated, the STPs act as a carrier for their release into the environment e.g. 
carbamazepine (Clara et al., 2004, Ternes, 1998, Vieno et al., 2007).  
Within STPs pharmaceuticals are primarily eliminated by biodegradation and sorption 
(Castiglioni et al., 2006); however the main purpose of the STPs is to eliminate 
dissolved organic matter, nutrients and solids (Vieno et al., 2007). Given that many of 
the pharmaceuticals are hydrophilic (i.e. relatively low Kow and Koc values) their 
sorption to sludge is often limited. Many other factors affect the rate of elimination 
during sewage treatment e.g. treatment process type, dilution of raw sewage, 
temperature, solids retention time and hydraulic retention time. Elimination rates can 
vary from plant to plant and in the same plant at different time periods (Castiglioni et 
al., 2006). Investigations have demonstrated that a change in operating conditions 
(e.g. sludge retention time) can effectively improve the elimination of some 
pharmaceuticals (Cirja et al., 2008, Clara et al., 2005, Andreozzi et al., 2003). 
Therefore, comparison of operational/control strategies in STPs is a promising tool to 
test the relative removal effectiveness of these compounds.  
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Carbamazepine is well documented and a very persistent antiepileptic drug in the 
environment, making it a good ‘model’ pharmaceutical for anthropogenic influences 
in the environment. Carbamazepine removal is negligible and is reported by a number 
of studies at higher concentrations in the treated sewage rather than in the raw influent 
(from 20% upto twice as high) (Jones et al., 2005, Clara et al., 2004). The most 
probable explanation for this is the conversion of carbamazepine glucuronide and 
other conjugated metabolites back into the parent compound by enzymatic processes 
(Bahlmann et al., 2014). Cleavage of the glucuronic acid moiety is feasible in STPs as 
activated sludge (AS) has been found to have glucuronidase activity (Ternes et al., 
1999). The presence of a carbamazepine glucuronide was detected at higher 
concentrations in influent waters and negligible detection in effluent wastewaters 
supporting this pathway (Vieno et al., 2007). However, this might not be the case for 
all pharmaceuticals. Elimination efficiencies range from > 80% i.e. norfloxacin, to 
moderate elimination (40-80%) i.e. acebutolol to poor elimination <40% i.e. 
metropolol and show no elimination i.e. carbamazepine (Vieno et al., 2007). Table 
2.4.1 shows the structure of these four example drugs and their physical chemical 
properties. The Table illustrates the diverse range of pharmaceuticals that are released 
into in our sewage wastewaters and receiving waters.  
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Table. 2.4.1 Important Pharmaceuticals representing different ATC classes along with 




MW (g/mol) = 236.3 MW (g/mol) = 267.4 
Water solubility (mg/L) = 17.7 Water solubility (mg/L) = 4780 
Log Kow = 2.45 
Removal efficiency = -121% (Vieno et al., 
2007) 
Log Kow = 1.69 





MW (g/mol) = 336.4 MW (g/mol) = 319.3 
Water solubility (mg/L) = 259 Water solubility (mg/L) = 178000 
Log Kow = 1.71 
Removal efficiency = 47% (Vieno et al., 
2007) 
Log Kow = -1.03 
Removal efficiency = nd (not detected) 
(Vieno et al., 2007) 
 
The literature offers a wide range of studies with extensive measuring campaigns 
analysing the occurrence of pharmaceuticals in STP influent and effluent wastewaters. 
Table 2.4.2 shows some highly consumed pharmaceuticals and a corresponding study 




Table 2.4.2. STP influent and effluent concentrations of highly consumed 
pharmaceuticals 
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Only human exposure is monitored during drug development and this scrutiny is not 
always extended to the negative impact that they can cause in the environment. In 
many cases, these pollutants can pose a significant risk on the environment and 
human health (Ternes et al., 2004). There is a surplus of literature addressing the 
potential adverse effects of pharmaceuticals in the environment, but only a handful of 
studies report effects such as changes to hormone synthesis, reproduction and 
mitochondrial oxidation metabolism (Pagano et al., 2001, Nash et al., 2004, Mimeault 
et al., 2005). Several studies report adverse affects in fish in estrogenic effluents when 
comparing populations of upstream and downstream wild fish, where results show 
that fish living downstream from a STP discharge exhibit severe signs of endocrine 
disruption notable as a higher proportion of intersexed fish (Vasquez et al., 2014, 
Williams et al., 2003).  
With over 50,000 pharmaceuticals commonly used today, risk assessments have been 
made to help predict the chemicals that are likely to be hazardous to the environment 
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before adverse effects are seen on the aquatic ecosystem. Currently the most common 
method for assessing the environmental risk of pharmaceuticals is by deriving a 
predicted no effect concentration (PNEC) from available toxicity data. The PNEC can 
be compared to a predicted environmental concentration (PEC) based on usage 
projections. This strategy is required in both the US and EU to assess the 
environmental risk of a prospective pharmaceutical. However, most of the drugs 
detected in environmental compartments were approved before environmental toxicity 
testing paradigms were established. Rigorous pharmaceuticals testing during their 
preclinical and clinical development allows determination of dose-response for 
beneficial and adverse effects demonstrated in their No-Observed-Effect-Levels 
(NOELs) and Low-Observed-Effect-Levels (LOELs). 
Prioritising pharmaceuticals for environmental monitoring and/or risk assessment 
purposes was identified as a major research need (Boxall et al., 2012) where many 
publications prioritise by categorising consumption, therapeutic class, mode of action 
(MoA) or physical-chemical properties (i.e. lipophilicity) (Besse et al., 2012, 
Caldwell et al., 2014, Berninger and Brooks, 2010, Roos et al., 2012, Kostich and 
Lazorchak, 2008, Dong et al., 2013). After review of prioritisation methods, Caldwell 
et al 2014, proposed an approach with 3 steps to identify and prioritise substances for 
prospective and retrospective risk assessments. Step 1 makes use of mammalian 
pharmacological data i.e. the maximum plasma concentration after drug 
administration (Cmax). Step 2 involves consideration of the lipophilicity across 
environmentally relevant pH ranges and ionization potential and thus bioavailability 
of a specific pharmaceutical. Such a consideration is critical because over 70% of 
therapeutics are ionizable at environmental pHs (Caldwell et al., 2014). The final step 
is to use exposure modelling software to further refine the priority list by considering 
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the quantity of the pharmaceutical sold and induced into the environment by adjusting 
the metabolised and removed fractions from STPs (Caldwell et al., 2014).  
Are pharmaceuticals an emerging environmental problem or is it just the analytical 
advances that make them detectable now, when in the past they were present but 
invisible (Taylor and Senac, 2014). Pharmaceuticals are diverse in structure and don’t 
have similar chemical, physical, structural or biological similarities, the common 
factor that unites them as a group is use (Taylor and Senac, 2014). They are designed 
to be biologically active, and therefore considered more harmful. Some 
pharmaceutical sub-groups may be more toxic than others such as the antineoplastic 
and immunomodulating agents (ATC class L01). The chemicals in L01 largely target 
DNA and are cytotoxic in action causing subtle genetic alterations that have the 
potential to cause long term adverse effects in the aquatic environment. There is a 
need to perform a risk assessment on the sub-groups of pharmaceuticals to determine, 
which if any are detrimental to the environment. ‘Down the drain’ chemicals don’t 
exist solely in the aquatic environment and are present as a mixture of many diverse 
pharmaceuticals which may act additively enhancing their negative effects.  
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3. Anticancer drugs  
Cancer is a major public health concern with significant mortality, in 2011 over 
338,000 newly diagnosed cancers were registered in the UK (Table 3) and 14.1 
million in the world were diagnosed in 2012. There is high associated mortality with 
cancer, with approximately 8.2 million deaths in 2012 worldwide. There are more 
than 100 different types of cancer, the four major cancers accounted for 54% of the 
diagnosed cancers in 2011 (UK), breast cancer (15%), lung cancer (13%), prostate 
cancer (13%) and bowel cancer (13%). Chemotherapy is administered in a 
standardised regimen, where one or more chemotherapeutic agents are dispensed with 
the intent to prolong life, reduce symptoms (palliative chemotherapy) and/or provide a 
curative response in the patient. Chemotherapy is one of the major categories of 
medical oncology, as is often applied in combination with radiation, surgery and/or 
hyperthermia therapy. Some chemotherapeutic agents are used outside the ATC L01 
classification and used in the treatment of other conditions, including multiple 
sclerosis and Crohn’s disease. In 1941, a patient diagnosed Hodgkin’s lymphoma was 
treated with an experimental drug found to be a hematopoiesis (blood production) 
suppressor after its use as a chemical warfare agent during WWI (Joensuu, 2008, 
Krumbhaar, 1919). The first chemotherapy drug to be developed from this research 
was mustine.  
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Table 3. UK cancers diagnosed in 2011 and their mortality in 2012. Statistics obtained 
from http://www.cancerresearchuk.org/cancer-info/cancerstats/keyfacts/ (Date 
assessed 5/03/2015) 
Type No. of diagnosed cancers 
in 2011 (UK) that 
contribute to more than 
1% of the cancer burden 
No. of cancer mortality in 
2012 (UK)  
Breast 49936 11643 
Lung 43463 35371 
Prostate 41736 10837 
Bowel 41581 16187 
Skin 13348 2148 
Non-Hodgkin lymphoma 12783 4676 
Bladder 10399 5242 
Kidney 10144 4252 
Cancer of unknown 
primary 
9762 10625 
Brain tumours 9365 5187 
Pancreatic 8773 8662 
Leukaemia 8616 4807 
Uterine 8475 2025 
Oesophageal 8332 7701 
Ovarian 7116 4271 
Stomach 7089 4758 
Oral 6767 2119 
Myeloma 4792 2742 
Liver 4348 4514 




Mesothelioma 2570 2429 
Laryngeal 2360 784 
Testicular 2207 63 
Other 17806 3037 
Total 338273 154080 
3.1. How cancer arises 
All cancers arise from genetic mutations that control cell growth and behaviour to 
allow the cell to be invasive and metastatic. Cancerous cells and normal cells undergo 
very similar cell division, but in many cases cancerous cells exhibit loss of control of 
the cell cycle and deregulation leads to tumour formation. Abnormalities in a cancer 
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cell cycle include rapid cell division, failure to arrest the cell cycle at checkpoints and 
failure to trigger programmed cell death (apoptosis) in the presence of damaged DNA 
(CHAFFEY, 2003). Both environmental and genetic factors lead to the accumulation 
of genetic mutations in oncogenes (genes that promote cancer) i.e. cell cycle 
inhibitors (p53) (Bian et al., 0000). Figure 3 shows the normal somatic cell cycle 
which consist of two alternative phases; S phase (DNA is replicated) and M phase 
(Mitosis where cell division produces two daughter cells). A checkpoint in the middle 
of mitosis ensures the cell is ready to divide. Gap 1 is where the cells increase in size 
and go through a checkpoint prior to DNA synthesis. Gap 2 is between DNA 
synthesis and mitosis, the cells continue to grow and go through another checkpoint 
control to ensure that everything is ready to enter mitosis.  
Figure 3.1 Schematic of normal cell cycle control; M (mitosis), G1 (gap 1), S 
(synthesis), G2 (gap 2) 
3.2. Chemotherapy and types of anticancer drug 
The majority of chemotherapy drugs act by targeting the cellular processes of rapidly 
dividing cells and impairing mitosis. Mitosis is prevented by a number of 
mechanisms, traditional chemotherapeutic agents (cytotoxic) interact with the DNA 
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and the cellular components relevant for cell division. Understandably, cancers such 
as acute myeloid leukemia (AML) with high growth rates are more sensitive to 
treatment with chemotherapeutic drugs than tumours with slower growth rates, as a 
higher proportion of cells are undergoing cell division at any time (Corrie, no date). 
The cytotoxic agents are non-cell cycle specific and also harm healthy cells (bone 
marrow, digestive tract cells and hair follicles) resulting in the common side effects of 
chemotherapy (myelosuppression, mucositis and alopecia). Modern anticancer drugs 
(monoclonal antibodies) are considered to be a ‘targeted’ chemotherapy and target 
proteins (essential for growth) that are overexpressed in malignant cells.  
3.2.1. Alkylating agents 
The cytotoxic alkylating agents are anti-proliferative in action as they covalently bind 
to DNA, RNA and proteins through their alkyl group (CnH2n+1) forming a crosslink to 
halt cell proliferation. The electrophilic alkyl group interacts with the nucleophilic 
nitrogen atom located on the purine ring of the guanine base in DNA (Figure 3.2.1) 
(Puyo et al., 2014). The alkylating agents can form intrastrand or interstrand 
crosslink’s, by binding to one or both strands of DNA, respectively. The crosslinking 
causes DNA strand breaks when the cell undergoes replication, thus inducing 
apoptosis. The alkylating agents are non-cell specific and act at any point during the 
cell cycle; therefore the cellular effect is dependent and directly proportional to the 




Figure 3.2.1. Crosslinked DNA by alkylating agent 
Some of the alkylating agents require activation into their active substances in vivo. 
For example cyclophosphamide an oxazaphosphorine alkylating agent is activated by 
liver cytochrome P450 (CYP) enzymes into 4-hydroxy cyclophosphamide that has 
therapeutic activity (Table 3.2.1) (Puyo et al., 2014). Ifosfamide (IF) is an analog of 
cyclophosphamide and has a similar range of anticancer activity (Weiss, 1991). Both 
CP and IF have adverse side effects, especially at higher doses, including 
neurotoxicity, nephrotoxicity (kidney toxicity) and/or bladder toxicity causing an 
onset of conditions i.e. bladder cancer (Weiss, 1991). Cyclophosphamide is on the 
world health organisations (WHO) list of essential medicines, where upto 580 
medications are listed (other alkylating agents on the WHO list shown by asterisk in 




Table 3.2.1. Alkylating agents (asterisk shows medications listed on WHO list of 
essential medicines) 
Nitrogen mustard analogues 
 
 
L01AA01 Cyclophosphamide* L01AA02 Chlorambucil* 
  
L01AA03 Melphalan L01AA06 Ifosfamide 
 
 










L01AD01 Carmustine L01AD02 Lomustine 
Other alkylating agents 
  
L01AX03 Temozolomide L01AX04 Dacarbazine* 
 
3.2.2. Antimetabolites 
Antimetabolites are cell-cycle dependent and act during the S-phase of replication, by 
impeding DNA and RNA synthesis. Many have similar structures to the nucleotides 
of DNA and RNA; guanine (G), adenine (A), cytosine (C), thymine (T) and uracil (U) 
(RNA only). The antimetabolites have well defined MoA and act by interfering with 
cellular processes required for DNA synthesis (incorporation into DNA/RNA or by 
inhibiting enzymes) leading to programmed cell death (Peters et al., 2000). Since the 
antimetabolites only work in the synthesis phase, increasing the dose does not 
increase their efficiency of treatment.  
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Table 3.2.2. Antimetabolites (asterisk shows medications listed on WHO list of 
essential medicines) 
Folic acid analogues 
L01BA01 Methotrexate* L01BA04 Pemetrexed 
Purine analogues 
L01BB02 Mercaptopurine* L01BB03 Tioguanine* 
L01BB04 Cladribine L01BB05 Fludarabine 
Pyrimidine analogues 
L01BC01 Cytarabine* L01BC02 Fluorouracil* 
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L01BC03 Tegafur L01BC05 Gemcitabine 
L01BC06 Capecitabine L01BC07 Azacitidine 
3.2.3. Plank alkaloids and other natural products 
The vinca alkaloid chemotherapy agents target a ubiquitous polymer with an essential 
role in cell division, the microtubules. Tubulin, the building block of microtubules is a 
globular protein targeted by this class of anticancer drug. Vincristine, vinblastine and 
vinorelbine (Table 3.2.3) are often used to treat haematological cancers (leukaemia) 
(Stanton et al., 2011). Where vinblastine inhibits the production of new blood vessels 
and vincristine destabilises tubulin by reversibly binding to the two sites. The 
reversible binding makes vincristine particularly powerful as it reattaches to another 
site, making the assembly of microtubules unsuccessful. Blocking the microtubules is 
essential to stop the formation of the cytoskeleton, responsible for maintaining the cell 
structure and providing a platform for intracellular transport and composing the 
mitotic apparatus essential for cell division. The predominate mode of action of the 
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vinca alkaloids is preventing the cancer cells from successfully dividing; therefore 
they are cytotoxic in action (Stanton et al., 2011).  
Table 3.2.3. Plant alkaloids and other natural products (asterisk shows medications 
listed on WHO list of essential medicines) 
Vinca alkaloids and analogues 
 
 
L01CA01 Vinblastine* L01CA02 Vincristine* 
 
 
L01CA03 Vindestine L01CA04 Vinorelbine 






L01CD01 Paclitaxel* L01CD02 Docetaxel* 
3.2.4. Cytotoxic antibiotics and related substances 
The anthracycline antibiotics are non cell cycle specific and therefore don’t require 
cells to be in a particular phase before their administration. They are used to treat 
many different cancers and are among the most effective chemotherapy agents 
developed but, cardiotoxicity as an adverse side effects limits their use (Minotti et al., 
2004, Weiss, 1992). Doxorubicin and daunorubicin were first isolated in the mid 20th 
century from Streptomyces peucetius with only small structural differences between 
them (Table 3.2.4), yet their usage in the chemotherapy regimens varies vividly. The 
antibiotic anticancer agents employ many different complex MoAs, by 
interfering/causing (1) oxidation damage (reducing oxygen to reactive oxygen 
radicals that cause damage to the cell membrane), (2) protein degradation (via 
proteasome interaction) within the cell and (3) blocking DNA replication by 
intercalating between DNA and RNA bases leading to apoptosis (Minotti et al., 2004). 
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L01DB01 Doxorubicin* L01DB02 Daunorubicin* 
 
 
L01DB03 Epirubicin L01DB07 Mitoxantrone 
Other cytotoxic antibiotics 
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L01DC01 Bleomycin* L01DC03 Mitomycin 
3.2.5. Other antineoplastic agents 
The platinum compounds (Table 3.2.5) are similar in action to the alkylating agents 
by causing crosslinking of DNA on the N-7 position of guanine, inhibiting DNA 
repair and/or DNA synthesis (Poklar et al., 1996). Another drug in this category is 
procarbazine, a methylhydrazine compound. Procarbazine undergoes hepatic 
metabolism to generate the active species, again it is similar in action to the nitrogen 
mustard alkylating drugs, except it doesn’t contain the fundamental chloroethyl group 
but instead an N-methyl group (Massoud et al., 2004).  
Other drugs in this category are the cancer growth inhibitors; they are a type of 
targeted biological therapy and include inhibitors such as; 
• Tyrosine kinase inhibitors, which block enzymes sending growth signals in the
cells (tyrosine kinases)
• Proteasome inhibitors, which block the proteasome enzymes that would
normally degrade surplus proteins in the cell, the build-up of surplus proteins
induces apoptosis.
• mTOR inhibitors, mTOR is a type of kinase protein that produces cyclins
(chemicals that trigger cell growth) and proteins for the development of new
blood vessels (an essential for cancerous cells to grow). In some types of
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cancer the mTOR is switched on, which makes cancerous cells grow and 
produce new blood vessels, these inhibitors stop this growth.  
• PI3K inhibitors, PI3K act like switches in the cell (turn on proteins such as
mTOR – making a cancerous cell grow and multiply). In some cancers P13K
is permanently switched on, the hope is that in future treatments blocking the
P13K helps stop the uncontrollable growth of cancer cells, at the moment
these drugs are in clinical trials.
Table 3.2.5. Other antineoplastic agents (asterisk shows medications listed on WHO 
list of essential medicines) 
Platinum compounds 






Protein kinase inhibitors 
 
 




L01XE07 Lapatinib L01XE08 Nilotinib 
Other antineoplastic agents  
 
 
L01XX05 Hydroxycarbamide* L01XX17 Topotecan 
 
 
L01XX19 Irinotecan L01XX23 Mitotane 
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3.3. Anticancer drugs in the environment  
Anticancer drugs can enter the environment in the same ways as other 
pharmaceuticals. For example, after administration, they are metabolized and excreted 
via urine or faeces. The anticancer drugs have a wide range of metabolism rates and 
some are excreted in urine in high quantities i.e. over 75% of methotrexate and 
pemetrexed are excreted as the unchanged parent drug (Blum et al., 2002, Sweeney et 
al., 2006). Other anticancer drugs such as chlorambucil and capecitabine are readily 
metabolised and less than 5% are excreted in the urine as the parent drug (Alberts et 
al., 1979, Straub, 2010). In general the anticancer drugs are highly polar with high 
aqueous solubility (Booker et al., 2014). They enter sewage treatment plants and are 
inefficiently removed in STPs, which rely largely on activated sludge mediated 
through hydrophobic interactions. Biodegradation of anticancer drugs depends largely 
on the environmental conditions; most anticancer drugs are not readily biodegradable 
and are considered to be semi-persistent compounds due to their continual release into 
the environment (Jones et al., 2005). Most anticancer drugs have half-lives of 2 days 
and environmental persistence times of 8 days (predicted from EPI SUITE). Some 
STPs have UV systems in place as part of a final treatment; however anticancer drugs 
such as cyclophosphamide do not have absorption spectra in the UV-range and hence 
do not undergo direct photolysis. The removal of CP and other anticancer drugs by 
conventional STP processes is often incomplete and inefficient (Lutterbeck et al., 
2015). A select few anticancer drugs have been detected in surface waters at dilute 
trace levels (low ng/L range). These include cyclophosphamide, ifosfamide, 
gemcitabine, cytarabine, bleomycin and tamoxifen (Buerge et al., 2006, Zuccato et al., 
2000, Valcárcel et al., 2011, Martín et al., 2011, Coetsier et al., 2009).  
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The anticancer agents are dangerous environmental contaminants that have potent 
mutagenic, teratogenic, cytotoxic, carcinogenic and/or endocrine disruptor effects in 
several organisms. They are designed to disrupt and prevent cellular replication by 
interfering with DNA, RNA and critical pathways, triggering apoptosis of the 
cancerous cell. After more than 50 years, CP is still a widely used chemotherapy 
agent worldwide, it has been detected in water bodies and known to be persistent in 
the aquatic environment. Yet there is still uncertainty over the levels of 
contamination, persistence and ecotoxicity of this drug in the aquatic environment.   
32 
4. Methodology
This chapter presents the analytical methods, laboratory protocols and instrumentation 
for the analysis of cyclophosphamide and ifosfamide using liquid chromatography 
tandem mass spectrometry (LC-MS/MS) in the aquatic environment. The first 
approach in 1996 measured CP and IF in hospital wastewaters by gas chromatography 
coupled with mass spectrometry (GC-MS) using CP derivatives for internal 
standardization, aiding a detection limit of 7 ng/L for IF and 6 ng/L for CP (Steger-
Hartmann et al., 1996).  It is now a common approach to quantify pharmaceuticals 
with LC-MS/MS using a triple quadrupole (Q1q2Q3) because of its specificity and 
selectivity for the analysis of pharmaceuticals in complex environmental samples 
(Nussbaumer et al., 2011). For CP and IF Q1q2Q3 methods give detection limits of 
2ng/L, some methods report limits of detection (LOD) below 1ng/L (Llewellyn et al., 
2011, Buerge et al., 2006, Castiglioni et al., 2005, Yin et al., 2010). In these methods, 
target compounds are extracted either using one or various solid phase extraction 
(SPE) protocols.    
4.1. Tested compounds  
Cyclophosphamide ((RS)-N,N-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-
oxide) and ifosfamide (N-3-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amide-2-
oxide) were analysed in this study. Ethanol was originally used to dissolve CP and IF 
to ensure the dissolution of the powered standard. All standards were kept in a freezer 
below -80°C where no degradation occurred. An custom internal standard of 
deuterated cyclophosphamide (d4-CP) was used to aid quantification.  
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4.2. Sample collection 
Water samples for the majority of studies have been collected in glass amber bottles 
to avoid photodegradation. In this study the samples were collected in 2.5L amber 
glass bottles pre-washed and methanol rinsed. On sample collection the bottle was 
rinsed with the sewage water/receiving water at the sampling point. Samples were 
kept cool and extracted within 24 hours. All samples were returned to the laboratory 
where they were stored in the dark at 4°C, filtered (GF/F filters, Whatmann, UK) and 
spiked with d4-CP within 24 - 48 hours.  
4.3. Solid phase extraction 
Solid phase extraction is an important technique used in the sample pre-treatment for 
HPLC, where existing literature indicates SPE as an efficient method of extracting 
and recovering pharmaceuticals from water samples (Zuccato et al., 2000). SPE is 
used for six main purposes in sample preparation (1) removal of interferences, (2) 
concentration of the analyte, (3) desalting, (4) solvent exchange, (5) In situ 
derivatization and (6) sample storage and transport. In this study SPE was used to pre-
concentrate and remove interfering compounds. A typical SPE disposable cartridge is 
depicted in Figure 4.3 with an overview of the processes involved. The application of 
SPE generally involves four steps (letters denote the steps in Figure 4.3): 
a) Conditioning the packing bed: The conditioning step removes any impurities
and allows the sorbent to be solvated. Methanol is a commonly used
conditioning agent for SPE
b) Sample application: The sample is loaded onto the cartridges in a weak solvent
to allow strong retention of the analyte to the cartridge
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c) Washing the packing: Removes interferences from cartridge by washing with 
an intermediate strength solvent that retains the analyte of interest on the 
cartridge and removes other impurities 
d) Recovery of the analyte: Elution of the analyte fraction using a strong elution 
solvent.  
 
Figure 4.3. SPE cartridge and SPE application (a) conditioning, (b) loading, (c) 
washing and (d) elution 
The basic procedure from primary extraction to preparing the LC-MS/MS sample vial 
was as follows: Strata X 500mg-6mL SPE cartridges were selected as a sorbent for 
primary extraction based on their ability to retain polar compounds. The cartridges 
were loaded onto the autotrace SPE platform and sequentially conditioned with 12 mL 
ethyl acetate, 12 mL methanol and 12 mL of water at a flow rate of 5 mL/min. The 
sample lines were pre-cleaned with 25 mL isopropanol and 25 mL of water to prevent 
sample contamination. The pre-filtered 500 mL effluent samples were then pre-loaded 
at 6mL/min; an adequate flow rate to allow the pharmaceuticals to be drawn from 
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their solution (Buerge et al., 2006). Once loaded the sorbent beds of the SPE 
cartridges were washed with 12 mL HPLC grade water and then rinsed with a solution 
of HPLC grade water diluted with 40% methanol to remove interfering compounds. 
The Strata-X cartridges were then dried for 30 minutes by securing a 100 mL 
cartridge body filled with anhydrous calcium chloride to the inlet of the Strata-X 
cartridge using SPE column adaptors and drawing air through the stacked cartridges, 
allowing a solvent change to ethyl acetate for elution. The eluent goes through a 
second SPE step where the extract is cleaned using Florisil® cartridges in an off-line 
configuration. The final eluent 10mL 10% methanol dissolved in ethyl acetate (v/v) is 
collected in a 10 mL round bottom test tube and reduced to dryness using a nitrogen 
TurboVap® 214 LV (Biotage, Uppsala, Sweden) set to 40 ⁰C and 10 psi. The samples 
are then dissolved in 500µL mobile phase, vortexed and syringe filtered (0.2 µm, 
PTFE) into labelled LC vial ready for analysis by HESI-LC-MS/MS (Heated 
electrospray ionisation).   
4.4. Chromatography and identification 
It is evident from the literature that a variety of analytical techniques are capable of 
detecting the anticancer drugs in wastewaters, including high performance liquid 
chromatography (HPLC) or gas chromatography (GC) coupled with ultraviolet (UV) 
or mass spectrometry (MS) detection. The anticancer drugs are more commonly 
analysed by HPLC.  
4.4.1. Liquid Chromatography  
Chromatography is the physical separation of compounds by their distribution 
between two phases; a stationary phase and a mobile phase. A mobile phase is 
described as a liquid, gas or supercritical fluid which percolates through or along the 
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stationary bed in a definite direction. Figure 4.4.1 shows a schematic of the HPLC 
system.  
The chromatography parameters defined during method development and used in this 
study are as follows. Solvent A (0.1% formic acid in water) and solvent B (0.1% 
formic acid in methanol) were pumped at a predefined flow rate of 300µL/min into a 
mixing chamber. The sample was then automatically injected using the 10µL partial 
loop injector mode. Reverse phase chromatography (RPC) was achieved by using a 
packed µPLC Hypersil GOLD C18 column (50 x 2.1 mm 1.9 µm). RPC allows the 
most polar components of a sample to elute first, increasing the mobile phase polarity 
and elution time. For the Accela LC, the column oven was set to 50⁰C and analytes 
were eluted from the column using the following gradient programme: mobile phase 
A - 0 min, 95%; 15 min, 0%; 15.5 min, 95%, 20 min, 95%; using these conditions IF 
eluted at approximately 5.34 minutes and CP at 5.74 minutes. To minimise MS/MS 
source contamination, the LC flow was only diverted to the MS/MS between three 
and eight minutes of the acquisition period. 
Figure 4.4.1. Schematic of HPLC 
Sample 
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4.4.2. Mass spectrometry 
A detector must be used to confirm the identity of an analyte. Mass spectrometry 
stands out in the literature as the most popular method of detection and consists of 
three main stages; ionization, separation and detection.  The MS/MS was operated 
using a heated electrospray ionisation (HESI) and an atmospheric chemical ionisation 
(APCI) source. Ionisation firstly involves vaporizing the sample with a nebulizer 
(nitrogen gas) and bombarding with high energy electrons at a typical energy of 70eV, 
both the polarity and molecular weight of the compound determine the best source for 
ionisation. One of the main advantages of ESI is that thermally labile compounds may 
be ionized without degradation. For CP and IF a single electron is removed from the 
analyte causing them to become positively ionized and produce a cation (M+) with a 
m/z ratio equal to the analytes molecular weight. CP and IF were analysed with both 
APCI and HESI to see which source obtained the best response. 
Once the analyte has been ionized they are separated by their m/z ratios. The 
separation technique described for this study is the high resolution triple quadrupole. 
The quadrupole mass filter consists of four parallel 250mm hyperbolic rods with an 
internal diameter of 6mm where one pair of rods is exposed to a positive direct 
current (DC) and the other pair is applied with a negative DC. Ions are directed into 
the quadrupole and oscillate in the electric field. Radio frequency (RF) is applied to 
both rod pairs but one pair is 180⁰ out of phase. Varying RF and DC voltages 
systematically alters the trajectory of the ions through the rods and determines which 
m/z ratios are allowed to reach the detector. Tandem mass spectrometry involves 
three sets of quadrupole rods in series to enhance ion separation and detection. The 
first set of rods involves mass separation; the second set of rods is used as a collision 
38 
 
cell to cause fragmentation of the ions transmitted by the first set of rods. The 
fragmented ions from q2 are channelled into q3 according to their m/z ratios. Data is 
then collected on the ions structural properties and molecular weight.  
The critical part of optimizing MS/MS is choosing a scanning mode suitable for the 
particular analyte. The two main types of scanning mode are Full Scan (FS) and 
Selected Ion Monitoring (SIM). The total ion current (TIC) plotted from running in 
FS traces the ion current and as a compound is eluted from the HPLC column the 
relative intensity increases and forms a peak, compounds of every mass are plotted in 
the TIC. Sensitivity for FS will be far less than what is observed in the SIM 
experiment. SIM monitors over a very small mass range, where the narrower the mass 
range the more sensitive and only selected compounds are detected and plotted. In this 
study highly selective reaction monitoring (HSRM) was used, a unique fragment  ion 
produced in q2 is monitored and quantified providing the most sensitivity for both CP 
and IF. CP and IF tuning was carried out by directly infusing standards (~1mg/L) into 
the HESI source and MRM transitions, tube lens voltage and collision energies were 
recorded. The most abundant ions were identified and automatically optimised for 
both CP and IF. Table 4.4.2 shows the MS ion source parameters. 
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Table 4.4.2. MS Ion source parameters 
Parameter HESI 
Polarity Positive 
Spray voltage (V) 3000 
Vaporiser temperature (°C) 350 
Sheath gas pressure (arbitrary 
units) 
30 
Ion sweep gas pressure (arbitrary 
units) 
0 
Auxiliary gas pressure (arbitrary 
units) 
30 
Ion transfer capillary temperature 
(°C) 
300 
Collision gas pressure (mTorr) 1 
Skimmer offset voltage (V) -5
4.4.3. Data analysis and quantification 
Chromatogram peaks and analyte calibration curves were integrated using the ICIS 
algorithm of Xcalibur™ 2.0.7 by Thermo Fisher Scientific. A linear analyte 
calibration curve was generated using 1/X weighting with six calibration standards 
prepared at the following concentrations CP – 0.086, 0.43, 0.86, 1.72, 3.44, and 5.16 
ng/L; IF – 0.055, 0.28, 0.55, 1.11, 2.21, and 3.32 ng/L with the internal standard (d4-
CP) at a constant level of 5 µg/L. For each analysis sequence, calibration standards 
were bracketed around a maximum of eight unknown samples. Mobile phase blanks 
with and without d4-CP were used to check for carryover and the purity of the 
internal standard and the instrument was initially run with pure MeOH prior to each 
analytical run. Calculations were performed using area ratios of CP and IF on the IS 
(d4-CP). Recovery of IS d4-CP was ~20% greater for APCI (+) than HESI (+), the 
lower HESI wastewater recoveries were perhaps due to matrix effects associated with 
the nature of the samples, signal suppression is significantly more pronounced in 
HESI than for APCI. It has been proposed that ion suppression is a manifested effect 
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of competition for ionisation caused by the occurrence of non-volatile solutes in 
complex extracts, rather than the loss of charge on the analyte due to gas phase 
reactions that may occur in APCI (King et al., 2000). APCI provided a better overall 
recovery but with slightly higher instrumental limits of detection (LOD). MDLs for 
CP ranged between 0.03 - 0.12 ng/L, and between 0.05 - 0.09 ng/L for IF.  
A specific method was developed for the determination of other anticancer drugs, 
methotrexate (MT) and doxorubicin (DOX) with internal standarisation using 
deuterated methotrexate and doxorubicin. The most successful combination was 
found to be Strata-X-solid phase extraction cartridge conditioned and loaded with 
formic acid (0.1%) and EDTA (3%), followed by a 30% methanol clean-up. After the 
pre-concentration step the cartridge was dried and eluted with 10mL of HPLC grade 
methanol. The elute was concentrated under N2 and reconstituted in 500μL of mobile 
phase. DOX and MT tuning was carried out by directly infusing standards (~1mg/L) 
into the HESI source and MRM transitions, tube lens voltage and collision energies 
were recorded. The most abundant ions were identified and automatically optimised 
for both DOX, MT and their deuterated internal standards. The mass spectrometer 
was operated in highly selective reaction monitoring (HSRM) mode, significantly 
reducing matrix noise and improving sensitivity. The selective reaction monitoring 
chromatograms of DOX, MT, CP and their deuterated internal standards are shown in 
Figure 4.4.3.  
Figure 4.4.3. Selective reaction monitoring chromatograms of DOX, MT, deuterated-




5. Discussion of results  
5.1. Paper I 
After some six decades of worldwide use and increasing developments in cancer 
therapy, it is timely to review the fate and occurrence of the accumulative number of 
anticancer drugs available and likely to be present in the aquatic environment. 
Furthermore, there has been growing concern within the scientific community to 
better understand the fate of these chemicals in STPs and receiving waters. Collated 
data on concentrations in hospital wastewaters, STP influents and effluents and 
receiving waters indicate that some anticancer drugs are poorly degraded during 
treatment and infiltrate into the environment on both a regional and global scale and 
hence exhibit a ubiquitous environmental occurrence. Additionally accurate 
consumption of 65 anticancer drugs in a NW England hospital survey along with their 
physical-chemical profiles gives insight into their partitioning and fate within aquatic 
systems. Where the anticancer drugs remain dissolved in the aqueous effluent is 
fundamental for chemical breakthrough from the STP and their occurrence in surface 
waters. Of the 65 anticancer drugs in use, approximately twelve drugs are recognised 
here as being sufficiently persistent to warrant inclusion in environmental screening 
programmes. Concentrations measured in surface waters for these chemicals are well 
below the EC50 values reported for a wide range of aquatic organisms. Despite the 
effects of anticancer drugs on aquatic biota being poorly understood a limited number 
of studies report 5-FU (5-Fluorouracil) as the most concern with ecotoxicity tests 
categorising the drug as ‘very toxic to aquatic organism’ (EC50 <<1mg/L).  However, 
only limited data is available on ecotoxicity testing for the anticancer agents and 
many assessments were made on QSAR derived EC50 values which doesn’t examine 
their low dose, long term exposure in the environment that is likely to cause subtle 
43 
effects due to the high cytotoxic potency of the agents. Furthermore this study has 
highlighted mitotane (o,p'-DDD) as an additional environmental threat with a log kow 
> 3 (with a corresponding high koc value) indicating a potential for sorption to particle
matter, bioconcentration in fish and dispersion to farmland following retention in the 
sludge at STPs.  
5.2. Paper II 
Previously, the occurrence of anticancer agents in hospital wastewaters has received 
considerable attention and various studies have contributed to the current knowledge 
regarding their concentrations in hospital effluents. Method detection limits have 
considerably improved over the past few decades and an increasing number of 
publications have arisen due to analytical advances. Feasibly the few previously 
undetected anticancer agents could be present in wastewater influents and effluents, 
however at levels below the methods detection limits. This paper presents new data on 
the occurrence of CP and IF within the influent and effluent wastewaters of 14 STPs 
in England, using a previously published analytical method with LODs of 0.12 ng/L 
and 0.09 ng/L, respectively. CP was frequently detected above the LOD (0.12 ng/L) 
whereas IF was detected in only 2 of the sampled STP effluents above the LOD (0.09 
ng/L). Furthermore, this study shows a significant difference when comparing the 
influent and effluent concentrations of CP for STPs which operated a tertiary 
treatment process. For CP, this is important as it is the first study that demonstrates 
the ability for CP to be reactivated from a metabolite complex (conjugate) to the 
parent form of the chemical, consequently increasing the output concentration of CP 
in STPs. Additionally this study evaluates CP in a river catchment study, showing its 
occurrence in surface waters and accumulation in rivers downstream of the STPs. 
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This significant finding raises awareness of the environmental concern for CP, 
especially its implications during periods of low flow.  
5.3. Paper III 
Removal processes (degradation, partitioning and sorption to sludge) act as major 
sinks for micropollutants during sewage treatment processes. The performance of STP 
processes in removal of CP and IF are crucial for understanding the fate, occurrence 
and risk they pose to the aquatic environment. It is well appreciated that STPs are 
major contributors of CP and IF to the aquatic environment. The structurally similar 
anticancer agents possess very similar physical-chemical properties and their removal 
is expected to be comparable, however their difference in occurrence may be more 
related to the drug use and their proximity to hospitals than their removal efficiency. 
Comparison of the treatment efficiency for two tertiary STPs revealed that the 
elimination of CP was very poor and effluent concentrations for both plants were 
frequently greater than the influent concentrations. IF was not detected in this study, 
which is reflective of its low consumption at the contributing hospitals.  Reactivation 
of CP (presumably a glucuronide conjugate of CP) to the parent analyte is shown in 
all three stages of treatment, but greatest reactivation occurs during secondary 
treatment whereby the input conjugate is transformed into the original compound.  
5.4. Paper IV 
CP has been found in to be ubiquitous in sewage influents, effluents and receiving 
waters.  This paper investigates the distribution and levels of CP in the environment. 
Samples were collected in a defined river basin in NE England with well documented 
hydrological information. The results demonstrate, that CP and IF are detected in the 
River Aire and River Calder and surprisingly at similar concentrations (average ~ 1 
ng/L). This study is the first for this drug classification to compare real environmental 
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data to modelled data. Based on modelling and our best fit model inputs we identified 
a moderate correlation to the measured data. Discrepancies occurred at the lower end 
of the River Aire and Calder where CP spiked above the predicted modelled 
concentrations. Indicative that an increased river flow doesn’t essentially cause CP to 
be diluted and instead illustrates that CP is accumulating within the catchment 
especially since the spike occurs far from a sewage effluent discharge. The 
cumulative effects of the sum of risk quotient values for the top priority anticancer 
agents within this catchment showed no risk in the River Aire or Calder, however 
long term studies for these pollutants are needed to define the environmental stress 




The compounds investigated in this thesis are examples of two widely used anticancer 
agents both nationally and internationally. However, consumption data for the broad 
class of anticancer drugs combined with rates of human metabolism provide an 
assessment of the likelihood of occurrence of these drugs in wastewaters and 
receiving waters. This approach, taking into account the environmental reactivity and 
partitioning to particulate matter in wastewater, provides a qualitative insight into 
their likely survival during wastewater treatment and ability to be discharged to river 
water. Only a small group of anticancer drugs from the 10s of chemicals in use are 
likely to be present in final treated effluent, although a significant number partition 
appreciably to particulate matter and are likely to end up in sewage sludge. Sludge 
provides a further route for the environmental dispersal of these chemicals, 
particularly if the sludge is subsequently applied to agricultural land although their 
reactivity and half-lives need investigating in sludge. This thesis has demonstrated the 
apparent limitations in predicting environmental concentrations based on consumption 
data and wastewater flow rates only. Predicted environmental concentrations for some 
of the anticancer drugs should therefore be treated with caution. For example, 
environmental water samples of CP contained levels ~2 to 10 fold lower than that 
predicted for influent and effluent wastewaters. CP has very low rates of degradation 
and elimination from wastewater streams in STP and this is likely to be mirrored for 
other similar, highly water soluble anticancer drugs. The fate of CP in STPs is 
confounded by the apparent positive mass balance whereby concentrations and hence 
loads increase as wastewater passes through the various treatment processes. Akin to 
some other pharmaceuticals, a fraction of CP is likely to enter a STP in raw influent 
as a partially metabolised form, which is subsequently transformed back to the parent 
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CP molecule, most likely through the action of microbes. This phenomenon may 
confound modelling predictions of river water concentrations if raw influent loads are 
used as the emission estimates, as these are likely to be biased low. Further 
measurement work is required in order to determine this metabolite and the process 
by which it is transformed back to CP (both biotic and abiotic processes).   The 
physical-chemical profiles of CP and IF indicate that these chemicals remain in the 
dissolved phase and will not be lost from wastewater streams either through 
volatilisation or through particle settling and are therefore discharged in the STP 
effluents to recipient waters. The recipient rivers have CP and IF concentrations 
present at approximately 1 ng/L, and are still detectable and quantifiable despite 
dilution far from STP effluent discharge points. CP shows accumulation downstream 
within river basin studies and this highlights the persistence of this chemical in rivers , 
with ongoing use/discharge of this drug likely to maintain levels in river and estuarine 
waters for the foreseeable future. While this thesis has chiefly focused on CP and IF -  
certainly with regards to environmental measurements -  the fate of another 10-15 
drugs that are in common use and possess similar physical-chemcial properties to CP 
and IF, is now warranted and should be subject to both human and ecological risk 
assessments. In the case of human risk assessment, exposure occurs through the 
abstraction of river water as a potable water supply.  The elimination of these drugs 
during water treatment processes is likely to be negligible given the lack of 
elimination during secondary and tertiary wastewater treatment, although remediation 
techniques such as activated-carbon filters need testing for this group of drugs. The 
river water concentrations measured in this thesis generally fall below those 
considered to cause harm in standard toxicity assays (i.e. LC50 or EC50 values). Given 
the genotoxic nature of many of these chemicals then alternative toxicity endpoints 
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may be warranted, as a defined safe-level is unknown. For example, genotoxicity 
assays performed on sentinel aquatic species (or their relevant tissues) may be called 
for. The ongoing use and consumption of chemotherapy agents in the UK and other 
developed nations will continue and may actually increase (given the ageing 
populations in these countries) in the next few decades. It is therefore prudent to 
initiate some type of monitoring campaign either for STP effluents or in receiving 
waters (particularly in catchments where river water is abstracted as a potable water 
supply). This type of programme, coupled to ecotoxicity assays, would prove useful 




7. Future research needs 
Research on the environmental fate and impact of potent pharmaceuticals like 
anticancer drugs is currently in its infancy. With regards to basic water pollutants like 
nitrate, phosphate, suspended particulate matter or heavy metals, there is very little 
published literature regarding the environmental occurrence and fate of these 
chemicals.  This thesis has largely focused on just two of these compounds, CP and 
IF, but has highlighted their widespread occurrence and persistency. Areas for 
additional research include: 
• There is a need for a robust multi-compound screening method able to detect 
‘priority’ anticancer agents in wastewater influents, effluents and receiving 
waters at concentrations ranging from sub to low ng/L.  
• Regional surveys on consumption need to be carried out to prioritise those 
compounds with the highest consumption and longest environmental half lives 
for environmental screening surveys.  
In addition to this, there are some anticancer agents that have relatively low 
consumption but possess physical-chemical properties that demonstrate likely 
removal from STPs via sorption to sludge. Some of these chemicals, such as mitotane, 
have significant environmental concern. Mitotane (or o,p’-DDD) is a chemical related 
to the DDT ‘family’ (dichlorodiphenyltrichloroethane) and hence can be considered 
as a persistent organic pollutant,  possessing a log Kow >5 and a very long 
environmental half-life (e.g. >6 months in soil/sediment) Mitotane is applied during 
end-stage chemotherapy in specialist oncology units in relatively large doses and in 
consequence the STPs serving these units may contain a significant load of this 
chemical in the sludge, where further problems are introduced if this sludge is 
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subsequently applied to agricultural land. There is therefore a research need to 
identify those anticancer drugs which are most likely to partition appreciably to 
sludge and persist in this matrix, with studies aimed at addressing the fate of these 
chemicals following sludge application to pasture/agricultural land. 
From the STPs investigated in this thesis - several with tertiary treatment processes – 
elimination of CP and IF was found to be very low (< 20%). The chemicals stay 
dissolved in the aqueous phase, resist biodegradation, UV degradation and other bio-
transformation processes. A further stage of tertiary treatment would be a beneficial 
addition to STPs in the UK, not only to remove this sub-group of chemicals but also 
to target other pharmaceuticals that have similar physical-chemical properties. Initial 
research has shown that advanced oxidation processes e.g. UV-light coupled to an 
oxidative agent like H2O2, may be sufficient to degrade CP and other similar 
anticancer drugs from wastewater effluents (Kim et al., 2009).  
The whole concept of anticancer drug fate and behaviour in the aquatic environment 
is an important area of future research and screening campaigns for other chemicals 
should be carried out in defined river basins. Along with aqueous degradation and 
photodegradation, studies could be focussed on realistic freshwater scenarios using 
environmentally relevant concentrations of the compounds. This could lead to 
valuable information on anticancer drugs degradation and the accumulation of 
anticancer drugs in river systems, particularly important for the river basins that 
extract potable water downstream of STPs.  
There is a lack of data regarding ecotoxicity for the anticancer agents and their effects 
on sentinel aquatic organisms. Where data does exist, it is expressed as a half 
maximal effective concentration (EC50) and the reported values are far greater than 
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the levels found in the wastewater effluents and river waters. The EC50 values give a 
good indication of the drugs potency, but since anticancer agents are cytotoxic in 
action and cause subtle genetic alterations to cells, their mutagenicity may appear 
over generations rather than days to weeks, depending on the organism in question. 
Some studies have derived ecotoxicity endpoints for these agents; however this has 
been demonstrated at concentrations far beyond the levels observed in river water. 
These agents have low dose toxicity and may still act negatively in the environment at 
these sub-low ng/L concentrations and insight into their long term effects would 
further focus environmental screening programmes.  
A final thought for further research would be to develop a passive sampler to monitor 
levels in freshwater systems and investigate the temporal trends (e.g. periods of low 
flow) of the contaminants. A passive sampler would also provide additional 
information on the diffusion and spatial distribution across catchment waters and 
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Paper I - 16
Table S2: Average urinary excretion rates of the unchanged parent drug 
% of administered drug excreted (i.e. not metabolized) 
<5% 5-15% 15-25% 25-45% 45-75% >75%
Chlorambuci
l
1, 2, 3, 4 
[1]
Busulfan





































































1, 2  
Doxorubicin


























































1, 2  
Cladribine
1, 2  
Fludarabin
e
1, 2  
Etoposide
1,
2, 3  
Daunorubi
cin


















































*** No available data (Urinary excretion data was not available for six L01X 
anticancer drugs) 
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Paper II - 1
Abstract 
The presence of anticancer drugs in wastewaters, effluents and surface waters are a 
growing environmental concern. However, environmental measurements 
encompassing wastewater, treated effluent and receiving water required to assess 
exposure from sewage treatment plants (STPs) are lacking. In this study, raw influent 
(n=16) and final effluent waters (n=16) from fourteen STPs were sampled across 
England for the presence of cyclophosphamide (CP) and ifosfamide (IF) – two widely 
used anticancer drugs – using a sensitive analytical method. CP was detected in both 
influent and treated effluent with mean (SD) concentrations of 4.1 ng/L (4.8) and 6.6 
ng/L (6.5), respectively. IF was only detected in four effluent samples (mean ~ 0.38 
ng/L (n=4)). Surveys along the rivers Calder, Darwen and Ribble (located in North 
West UK) demonstrate increasing loads of CP down the catchment. CP was present at 
5 of the 6 river locations with concentrations ranging from 0.41 to 3.71 ng/L. It was 
noted that CP concentration actually increased during treatment implying a 
deconjugation process was taking place.  This also confirmed its high persistence 
observed by previous authors. 
Paper II - 2
1. Introduction
Anticancer drugs are a wide group of pharmaceuticals that are receiving increasing 
attention as environmental contaminants, with an increasing number of studies 
reporting levels in wastewater (Llewellyn et al., 2011, Buerge et al., 2006, Zuccato et 
al., 2000, Martín et al., 2011). There are over 70 separate chemicals classified as 
antineoplastic and immuno-modulating agents that are subdivided under the 
Anatomical Therapeutic Chemical (ATC) classification scheme into five groups of 
chemotherapy agents. These include the two important groups of alkylating agents 
(L01A) and antimetabolites (L01C) (Booker et al., 2014).  
Consumption of anticancer drugs is approximately <10-100’s kg/yr on a country wide 
basis with cyclophosphamide (CP) and ifosfamide (IF) being two commonly used 
alkylating agents used in the treatment of a wide range of cancers (e.g. bronchial, 
breast and ovarian cancers as well as certain types of leukaemia) (Booker et al., 
2014).  Johnson et al. (2013) reported a 15 fold difference in CP consumption across 
Europe ranging from 2.3µg/capita/day (Finland, 2010) to 35.7µg/capita/day (Sweden, 
2010) with a mean consumption of 10.4 µg/capita/day (Johnson et al., 2013). A 
hospital survey conducted across NW England (2011) showed CP consumption 
ranged between 4.3-11.8 µg/capita/day  (Booker et al., 2014). IF is a synthetic analog 
of CP and is consumed to a lesser extent, only 1.2 µg/capita/day is consumed in NW 
England  (Booker et al., 2014). These drugs can be administered as a single active 
ingredient or in combination with other anticancer drugs to increase their efficiency, 
and are administered to patients residing in hospital as well as ‘out-patients’ living in 
the wider community. Metabolism for CP/IF is estimated to be ~55-85% of the 
administered dose, ensuring that urinary and fecal excretion and transport of 
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wastewater through STPs is the most significant route of entry of these chemicals into 
the wider aquatic environment (Booker et al., 2014, Rowney et al., 2009). 
Interest in this specialised group of pharmaceuticals as environmental contaminants 
has increased principally due to their deliberately toxic mode of action (Johnson et al., 
2008). The potential for these drugs to harm humans through water recycling in areas 
where river/lake water is abstracted for potable water supplies has provided a greater 
focus (Johnson et al., 2008). Long term exposure may cause subtle genetic alterations 
that may not be present in the limited number of toxicity tests carried out over one 
generation. Alkylating agents such as CP and IF act via a cytotoxic mode of action, 
CP (a prodrug) undergoes complex metabolic activation and detoxification by 
cytochrome P450 enzymes in the liver to liberate alkylating metabolites such as 4-
hyroxycyclophosphamide/aldophosphamide, which serve as the transport species for 
the  metabolites which can cross-link DNA (phosphoramide mustard and acrolein) 
(Chen et al., 1997). 4-hydroxyclophosphamide and aldophosphamide also undergo 
enzymatic oxidation detoxification to form inactive urinary excretion products 4-
ketocyclophosphamide and carboxyphosphamide respectively (Chen et al., 1997).   
Due to the toxic mode of action CP/IF could potentially induce genotoxic, teratogenic 
and mutagenic effects. Some suggest that the developmental vulnerability of an 
unborn child in the womb would be particularly susceptible to the teratogenic effects 
of chemotherapy drugs (Johnson et al., 2008). Major malformations, fetal death and 
spontaneous abortion have been reported with the use of CP during the first trimester 
(Cardonick and Iacobucci, 2004). Prognosis is better if CP is delivered during the 2nd 
and 3rd trimester where a review indicated that this exposure carries little risk of 
malformations (Amant et al., 2012) 
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Several authors have reviewed the considerable number of anticancer drugs used in 
chemotherapy, which when discharged may have harmful consequences for the 
environment (Booker et al., 2014, Johnson et al., 2013). Booker et al. (2014) 
highlights the highly consumed anticancer drugs in the North West (NW) England, 
which provides accurate consumption data and use patterns for the UK. Precise 
consumption data allows predictions on influent concentrations to be made to help 
corroborate analytical studies. Previous attempts have been made to predict the 
concentrations of anticancer drugs in the environment, where calculations were done 
from a theoretical point of view. The aims of this study was to comprehensively 
understand the occurrence and fate of CP and IF in STP influents, effluents and 
receiving waters; examining a range of STP plants that serve different population 
densities and possess different types of water treatment. This will allow an assessment 
of the removal efficiency of different STPs as well as providing valuable field data to 
determine chemical loads to surface waters. Furthermore, surface water 
concentrations of CP and IF are sampled in a defined river catchment in NW England 
(River Ribble). Measured river water concentrations together with previous calculated 
theoretical loads can be correlated as a tool for future predictions in catchment areas 
for anticancer drugs.  
2. Types of sewage treatment
Sewage treatment in England is managed by several private companies each with a 
regional base. This study conducted sampling at STPs from the following four 
companies United Utilities Plc (NW England), Severn Trent Water Ltd (Midlands), 
South West Water Ltd and Thames Water Utilities Ltd (London and Greater London). 
Table S1 (Supplementary information) summarizes data from the Water Services 
Regulation Authority (Ofwat) ‘June returns, Chapter 17 (2009)’ for the investigated 
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sewage works. The Ofwat classification for STPs classifies all treatment plants into 7 
discrete categories, suitable for discriminating between treatment processes in terms 
of pollutant removal efficiency.  
3. Materials and Methods
3.1. Sampling 
Wastewater samples were obtained from 14 STP located across North, South and East 
England over the period 2011-2012. The details of these STP types are described in 
Table S1 These plants operate 2 to 3 stages of wastewater treatment, involving 
physical separation of solids (primary treatment (P)) and secondary treatment 
(secondary activated sludge (SAS) or secondary biological (SB)). 71% of the STPs 
sampled had a third stage of wastewater treatment either Tertiary A2 (TA2) or 
Tertiary B2 (TB2) whose treatments include rapid-gravity sand filters, moving bed 
filters, pressure filters, nutrient control, disinfection hard COD and colour removal. 
TA2 works with secondary activated sludge plants and TB2 works with secondary 
biological process. Details of each STP installation, population equivalent and 
consents are provided in Table S1. 
The timings of sample collection involved in this project were considered, grab 
samples were collected between 10am and 2pm on weekdays to catch the morning 
sewage and to account for the CP and IF that is administered during outpatients 
clinics. In the first sampling campaign (locations 7 to 14) influent and effluent 
wastewater samples were collected proportionately to the flow over 24 hours 
‘composite’ samples (nano-filtered and frozen at -20°C on return to lab) and in the 
second sampling campaign (locations 1 to 6) influent and effluent samples were 
collected as 2.5L grab samples and stored at 4°C prior to extraction (extraction was 
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	conducted within 48 hours of sample collection). STP locations and the corresponding 
river catchment located in NW UK are shown in Figure 1. Sample site 7 was sampled 
twice; both samples obtained were 24hr integrated samples. Sampling was conducted 
during low-normal flow conditions with the exception of sampling site 10, which was 
conducted during a period of higher flow (≥100mm of rainfall per month)(Table S3). 
The river catchment study was carried out in NW England, centered on the River 
Ribble (the main river within the catchment) with a length of 194 km, draining a basin 
of 2227 km2, home to 1.25 million inhabitants. In parts the three predominant rivers, 
the Ribble, Darwen and Calder are densely populated and flow through large urban 
towns such as Preston, Blackburn and Burnley, respectively, with the rest of the 
catchment (90%) being predominately rural. The STP influent and effluent samples 
from locations 1 to 6 are located within the River Ribble catchment, a further six 
samples were selected on the Rivers Calder, Darwen and Ribble, largely close to the 
effluent discharge point (from a minimum of 50 m to a maximum of 11.3 km from the 
STP effluent discharge point), with further details presented in Table 1. Details of the 
six STP plants are listed in Table S1 and their locations are shown in Figure 1. 
Sample site 5 was visited twice, where one 2.5 L grab sample and one 24 hr time 
integrated sample was obtained. The river sample corresponding to site 6 is a sample 
from the River Ribble in Preston (11.3 km downstream from the effluent discharge at 
site 8 and 40 km from the effluent discharge at site 3), detailed in Table 1. The 
effluent water from site 6 (downstream of river sample) is discharged into a tidal 
estuary, draining into the Irish Sea.   
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3.2. Sample preparation and chemical analysis 
Chemical standards of cyclophosphamide monohydrate (2-[Bis(2-
chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide) and ifosfamide 
(N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine-2-oxide) were 
obtained from Sigma Aldrich (Gillingham, Dorset, UK) with chemical structures 
provided in Table S4 (Supplementary information). Custom-synthesized internal 
standard (IS) of deuterated-cyclophosphamide (d4-cyclophosphamide or d4-CP) was 
purchased from Qventas Laboratories (Branford, CT, USA), with HPLC-grade 
solvents purchased from Rathburn chemicals (Walkerburn, Scotland).  
Preparation and treatment of both time integrated and grab samples followed a 
previously described method (Llewellyn et al., 2011). In brief, 500 mL of each sample 
was initially filtered (GFF filters, Whatman, UK) and spiked with 5 µL of d4-CP IS 
for quantification purposes (resultant concentration approximately 15 ng/L). The 
filtrate was passed through a Strata-X (Phenomenex, Macclesfield; UK) SPE cartridge 
and eluted with 10 mL of HPLC-grade ethyl acetate. The ethyl acetate extract was 
then eluted through 200 mg of Florisil (Biotage, Uppsala; Sweden) and the resulting 
eluent concentrated under N2 and made upto 500 µL with the LC mobile phase 
(comprising ~95% water, ~5% methanol ~0.1% formic acid) and quantitatively 
transferred to 2 mL autosampler vials for analysis. All standards and extracts were 
stored in amber vials at -20°C prior to instrumental analysis.  
Analyses were performed on a LC-MS/MS instrument: an Accela high performance 
liquid chromatograph (Thermo Fisher Scientific Inc) coupled to a triple quadrupole 
‘Quantum Ultra TSQ’ mass spectrometer (Thermo Fisher Scientific, Hemel 
Hemsptead; UK) interfaced with an ion max electrospray ionisation (ESI) and 
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operated with Xcalibur software ™ (V.2.0.7.) Analyte separation (10 µL inj. volume) 
was performed on a µPLC Hypersil GOLD C18 column (50 x 2.1 mm 1.9 µm) using 
a H2O:MeOH mobile phase gradient (Llewellyn et al., 2011). Seven calibration 
standards ([IF] = 0.14-6.63 µg/L, [CP] = 0.22-10.33 µg/L, [d4-CP] = 5 µg/L) were 
freshly prepared in the mobile phase solvents for each analysis (Table S5 shows the 
prepared concentrations for CP and IF calibration) with the addition of 5 µL IS d4-CP 
to each sample and calibrant (resultant concentration 15 ng/L). Instrumental operating 
conditions are provided and in Table S6, with IF eluting at 5.34 minutes and CP at 
5.74 minutes with baseline separation for the two compounds. Chromatographic peaks 
were integrated using the ICIS algorithm of Xcalibur™ which was also used to 
generate linear calibration curves using a 1/X weighting. Analyte peak signal to noise 
(S/N-RMS) ratios were obtained with the manual noise region option in Xcalibur™. 
3.3. Quality control and assurance 
CP and IF calibration standards were freshly prepared for each analysis with 
calibration standards bracketed around no more than eight unknown samples and as 
such injected at least twice during each analytical run. All samples and standards were 
spiked with IS d4-CP (Llewellyn et al., 2011). The LC-MS/MS instrument was 
initially run with pure MeOH prior to each analytical run with mobile phase blanks 
(both with and without d4-CP) used to check for analyte carry over and purity-check 
of the IS. Calculations were performed using area ratios of CP and IF on the IS (d4-
CP). Ionisation of CP and IF was conducted via heated ESI (HESI), however, samples 
collected from locations 1-6 suffered from lower recoveries of the IS compared to 
samples collected from locations 7 to 14. Therefore atmospheric pressure chemical 
ionisation (APCI) was also tested, under both positive and negative polarity with 
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comparison of the two ionization modes (HESI and APCI). Likewise calculations 
were performed using area ratios of CP and IF on the IS (d4-CP).  
3.4. Recovery 
Recovery of IS d4-CP was ~20% for APCI (+) and > HESI (+) recovery. In general 
the average recovery for sample sites 1 to 6 using HESI was 41.0% for STP influent 
samples and 30.5% for effluent samples, whereas, the average recovery for the same 
samples using APCI was 82.3% (influent) and 37.3% (effluent). The lower HESI and 
effluent wastewater recoveries were perhaps due to matrix effects associated with the 
nature of the wastewater samples. Signal suppression in ESI was significantly more 
pronounced than for APCI for CP, IF and d4-CP. It has been proposed that ion 
suppression mainly involves changes in the droplet solution properties caused by the 
presence of non-volatile solutes in ESI of complex extracts, rather than gas phase 
reactions leading to the loss of net charge on the analyte that may occur in APCI 
(King et al., 2000).  APCI provided a better overall recovery but with slightly higher 
instrumental limits of detection (LOD). MDLs for CP ranged between 0.03 - 0.12 
ng/L, and between 0.05 - 0.09 ng/L for IF. The detected concentrations were far 
greater than the LOD and despite the increase in IS recoveries for samples run using 
APCI, the concentrations calculated for both ionisation modes were comparable.  
4. Results and Discussion
The first approach in 1996 measures CP in hospital effluent using gas 
chromatography-mass spectrometry (GC-MS) with CP derivatives for internal 
standardization described in Steger-Hartmann et al.  Previous attempts to quantify CP 
with GC-MS have reported limits of detection (LOD) of 6ng/L for CP. However, it is 
now the common approach to quantify with liquid chromatography-tandem mass 
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spectrometry (LC-MS/MS) using a triple quadrupole (Q1q2Q3). These methods give 
detection limits below 2ng/L (Castiglioni et al., 2005, Yin et al., 2010), with two 
methods reporting detection limits in the sub ng/L range (Llewellyn et al., 2011, 
Buerge et al., 2006). A review of the methodology for sampling, extracting and 
quantifying CP in the aquatic environment is detailed in Table S2 (Supplementary 
information).  
4.1. Cyclophosphamide/Ifosfamide in STPs 
CP was detected in 93% of wastewater influent and effluent samples, frequency of 
detection can be seen in Table 2. For grab sampling, three discrete samples were 
collected at each STP site and results combined to provide an average concentration. 
However, IF was only detected in one wastewater influent site (no. 12) and two 
wastewater effluent sites (no. 6 and 7). This low frequency of detection is shown in 
Table 2 and is likely to be attributed to the low UK consumption of IF. The lower 
frequency of detects and lower concentrations of IF relative to CP could be 
attributable to consumption patterns, only 50% of the NHS trusts surveyed in NW 
England consumed IF compared to 100% for CP (Booker et al., 2014).  
The CP concentrations were the highest with the influent and effluent concentrations 
ranging 0.43 -18.02 and 0.09 – 22.69 ng/L, respectively, whilst IF wasn’t detected 
(<0.12 ng/L) for influent wastewaters and <0.12 – 0.77 ng/L for wastewater effluents 
(Table 2 and S3). The STPs with the highest concentrations serve the major 
conurbations of Preston (population ~ 247,000), Fazakerly (population ~ 175,000) and 
Blackburn (population ~ 289,000) (Site numbers 6, 7 and 5 are shown in Figure 1). 
The concentrations for both CP and IF are several orders of magnitude lower than 
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those at which acute ecotoxicological effects have been reported to occur (mg/L) 
(Kümmerer et al., 1997).  
The CP concentration in STPs worldwide vary widely from <LOD to 13,100 ng/L in 
influent wastewaters, with the highest concentration reported in Spain, 2012 (Gómez-
Canela et al., 2012). For effluents CP ranges from <LOD to 20 ng/L, with the highest 
concentration reported in Germany, 1998 (Ternes, 1998). Whereas IF concentrations 
range within <LOD to 29 ng/L in wastewater influent from a variety of studies 
(Buerge et al., 2006), with the highest concentration being reported in Germany, 1997 
(Steger-Hartmann et al., 1997) and  range from <LOD to 2,900 ng/L in wastewater 
effluents, with the highest concentration reported in Germany, 1998 (Ternes, 1998). 
The per capita consumption of CP and IF in England in 2011, was approximately 40 
and 1 µg/cap/d, respectively. The European mean per capita consumption of CP 
between 1997 and 2011 was ~10 µg/cap/d (Booker et al., 2014, Johnson et al., 2013). 
The per capita consumption of CP and IF in Spain (2010) was approximately 75 and 
20 µg/cap/d (~2 – 20 times > consumption in the UK) explaining the wide variation in 
measured CP and IF in STP plants internationally. Several studies have measured 
concentrations of CP in STP effluents, with concentrations ranging from 2.1 – 4 ng/L 
in Zurich (2006), 12 ng/L in Montreal STP (2011), 2.5-4 ng/L in another Canadian 
study in 2006 and concentrations < 1 ng/L in Italian and Spanish studies (Buerge et 
al., 2006, Gómez-Canela et al., 2012).  A UK study reported CP between 0.2-3.6 ng/L 
in two STP plants (Llewellyn et al., 2011). The measured values in this study are 
within the predicted and detected ranges for CP (Booker et al., 2014) (Mean influent/ 
effluent CP concentration are 4.1 and 6.6 ng/L, respectively).   
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Booker et al 2014 predicted CP to be present in raw influent waters to be 41.5 ng/L. 
This is 10 fold higher than the average UK measured CP value in this study, this value 
falls outside of the measured range perhaps due to; (1) an assumed consumption rate 
derived from hospitals with higher than average CP concentration that is not 
comparable to the other areas sampled in the UK, (2) chemotherapy is often 
prearranged during outpatient clinics and so CP and IF might show daily 
concentration variations in STPs, (3) the modelled value was derived from predicted 
biodegradation rates and a set dilution per head of 200 L/day, where in fact the 
dilution to STPs may vary and be greater than this set value. STPs that receive 
hospital wastewater (large oncology unit) or densely population areas display 
concentrations closer to the predicted concentration (sites 5, 10 and 12). For example, 
the highest influent concentration detected in this study was 18.02 ng/L; the sample 
was measured from a sewage works that received the largest daily load of all the 
surveyed sites (site number 5).  
4.2. Cyclophosphamide behaviour during wastewater processing 
The concentrations detected in the effluent wastewaters were on average > 2-fold 
higher than raw influent water. The overall removal rate was calculated for all the 
composite time integrated samples during wastewater treatment (grab samples were 
omitted to evade discrepancies associated with any diurnal variation of CP levels). CP 
investigated in this study exhibited very different removal efficiencies, ranging from -
433% to 83% and the efficiency of the removal varied from one treatment plant to 
another. Figure 2 shows a summary of concentrations comparing influent and effluent 
wastewaters. There was a significant difference in the concentrations for the influent 
(mean 3.78±3.25 ng/L) and effluent (mean 8.72±6.94 ng/L) for the plants which 
operated a tertiary treatment process; t (9) =-2.27, p =0.05 (Fig 2c) but not for the 
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	other types (Fig 2a and 2b). These results demonstrate that the effluent waters contain 
higher concentrations of CP than the corresponding influent, particularly for plants 
which operated a tertiary treatment. 
The increase in the concentration of CP, namely “negative removal” during treatment, 
is a phenomenon reported in other studies for some pharmaceuticals and personal care 
products (PPCPs) (Besse et al., 2012, Ortiz de García et al., 2013, Yan et al., 2014). 
The chemical structure seems to be an important factor in determining removal rates. 
Ternes et al., 1998, demonstrated that medium polarity drugs are removed on average 
between 60% - 90%, whilst polar PPCPs exhibit lower removal during wastewater 
treatment (lower adsorption onto activated sludge particles).  Diclofenac is an 
example of a PPCP (log Kow = 4.51) that has been recovered in effluent wastewaters 
upto 95%, with some studies showing higher concentrations in the effluent because of 
desorption processes (Quintana and Reemtsma, 2004). CP is more polar than 
diclofenac and has a log Kow of 0.63 (Booker et al., 2014).  
This phenomenon of higher effluent concentrations may be attributed to the 
regeneration of CP during treatment could be related to deconjugation, a phenomenon 
frequently described for estrogens (Kumar et al., 2012). Whereby the glucuronide 
conjugates allow the complete transformation to the free parent compound within a 
sewer, preferably favourable in the STPs operating tertiary treatment with longer 
retention times. Li et al., 2010 demonstrate a minor CP glucuronide (alcophosphamide 
glucuronide) conjugate detected from CP treated mice, it is plausible that this type of 
compound could regenerate parent CP during sewage treatment. (Li et al., 2010).  
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4.3. Release of cyclophosphamide in receiving waters and chemical loads 
Table 2 presents the concentrations of CP measured in the rivers Calder, Darwen & 
Ribble located in NW England. The concentrations of CP detected in the STP influent 
and effluent wastewaters were multiplied by the average daily flow rate at each 
sampling site to obtain environmental loads, expressed in mg of CP per day (Table 
1).The sites are illustrated in Figure 1b and distances downstream from STPs are 
recorded in Table 1. CP was present at 5 of the 6 sampling sites, and IF was not 
present above the MDLs. 
With limited data available on the concentrations of CP and IF in UK waters, a 
modelling approach is desirable in order to quantify loads to river water from STP 
discharges and to verify existing modelling approaches. Booker et al., (2014) details 
the hospital consumption data for CP and IF for the hospitals located within the River 
Ribble catchment, whereby 18.1 kg/yr of CP is consumed (assuming a catchment 
population of 1.25million). Approximately a 21-fold dilution occurs within the 
catchment from effluent discharge point to the river water under low flow/normal 
conditions. Assuming an average human excretion rate for CP of 21% (Booker et al., 
2014) and considering that the STPs captured waste from 68.5% of the catchment 
population (1.25million), 1.8 kg/year is consumed within the Ribble catchment, of 
which 4.5% was present in the STP influents, 3.2% in the effluents and 2.4% in the 
river water (at site 6; after the confluence of the Calder and Darwen). We predicted 
CP concentrations would be within the ranges of 0.01 – 0.27 ng/L for this study, 
calculated from the measured effluent loads.  
CP was detected in river water samples between <LOD to 3.78 ng/L, with a mean of 
1.36 ng/L (±1.49 as shown in Table 3). Both values are consistent with previously 
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published data that predicted river water concentrations in North West England 
downstream of STPs to be 4.1 ng/L (Booker et al., 2014), and nationwide in France at 
>1.75 ng/L in sewage effluent which would equate to 0.18 ng/L in surface waters
using a 10-fold dilution from effluent to river water (Besse et al., 2012). 
Figure 3a illustrates the detected loads of CP for the River Calder (Sites 1, 2 & 3) 
(also illustrating the corresponding STP influent and effluent values). Figure 3b 
illustrates the detected loads of CP for the River Darwen (Sites 4 & 5) (also 
illustrating the corresponding STP influent and effluent values). Figure 3b shows each 
river with an increasing CP load down the catchment, both rivers flow into the River 
Ribble and the final site is located after the confluence (Site 6). The sites show an 
increase of CP from influent to effluent in all sites except site 5 (located on the River 
Darwen). This increase load is due to a high measured influent value principally due 
to sampling protocol and diurnal variation of CP. The final river water sample at site 6 
is located 40 km from the previous STP on the River Calder and 11 km from the 
previous STP on the River Darwen. River site 6 has the greatest load detected in the 
Ribble catchment, with a measured value of 0.41 ng/L (±0.08) and large river flow of 
approx. 2.89E+09 L/day (largest river flow in catchment), thus producing a high 
environmental load and illustrating that CP is maintaining within the catchment.  
To our best knowledge these data are the first which evaluate cyclophosphamide in a 
river catchment study, showing that cyclophosphamide does reach surface waters and 
shows accumulation in the rivers downstream of STPs. This may cause implications 
at times of low flow, where the subtle effects associated with low dose exposure will 
be an issue that requires further attention, particularly for anticancer drugs with high 
cytotoxic potency (Booker et al., 2014, Strong, 2012). In order to assess the 
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magnitude of the problem which is caused by release of anticancer drugs in 
environmental compartments, further toxicity testing at river level concentrations 
needs to be carried out with a larger array of chemicals.  
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Table 1: Environmental loads expressed in mg of CP per day. Sites 1 to 6 are 
contained within the River Ribble catchment (NW England). 















CP river load 
mg/d (distance 
downstream) 
1 5.80E+06 2.90E+04 2.67 1.97 <LOD (200 m) 
2 2.70E+07 2.53E+081 1.35E+05 11.64 32.24 58.22 (1.2 km) 
3 2.44E+07 7.46E+082 1.22E+05 12.59 122.71 432.42 (2.0 km) 
4 6.80E+06 6.80E+063 3.40E+04 11.90 93.18 25.70 (50 m) 
5 5.78E+07 3.67E+084 2.89E+05 1041.79 313.62 659.87 (1.3 km) 
6 4.94E+07 2.89E+095 2.47E+05 251.99 374.80 1183.76 (11 km 
from STP 8 and 
40 km from 
STP 3) 




8 8.20E+06 n/a 4.10E+04 30.70 33.14 
9 4.20E+07 n/a 2.10E+05 22.09 46.34 
10 3.98E+07 n/a 1.99E+05 367.91 653.63 
11 
12 
13 5.80E+06 n/a 2.90E+04 5.30 18.85 
14 1.10E+07 n/a 5.50E+04 <LOD 1.00 
*Data from the National River Flow Archive, CEH, river flow for day of sampling (or
thereabouts)
1 71010 – Pendle water at Barden Lane
2 71004 – Calder at Whalley Weir
3 Gauge station (71013) data not used, at point of sampling river flow was equal to
STP flow
4 71014 – Darwen at Blue Bridge gauge station
5 71001 – Ribble at Preston gauge station
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Table 2: Summary of all measured CP and IF concentrations, including the frequency 




Influent Effluent Influent Effluent 
Median 1.75 3.65 NA 0.33 
Mean 4.18 4.83 NA 0.38 
Min <LOD <LOD <LOD <LOD 
Max 18.02 16.42 <LOD 0.77 
SD 5.21 5.03 NA 0.29 
Frequency 
(%) 
93% 100% 0% 29% 
Values identified as < LOD are below the detection limit and not detected. 
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Table 3: Cyclophosphamide concentrations (ng/L) measured in triplicates in different 





Influent Effluent River 
1 0.46±0.03 0.344 <LOD 
2 0.43±0.03 1.19±0.32 0.23±0.18 
3 0.52±0.09 5.03±1.70 0.58±0.12 
4 1.75±0.06 13.70±1.41 3.78±0.21 
5 18.02±1.87 5.43±0.14 1.80±0.16 
6 5.10±0.22 7.59±0.54 0.41±0.08 
Median 1.13 5.23 0.58 
Mean 4.38 5.55 1.36 
Min 0.43 0.34 <LOD 
Max 18.02 13.70 3.78 
SD 6.92 4.84 1.49 
Frequency 
(%) 
100% 100% 83% 
Values identified as < LOD are below the detection limit and not detected. 
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Figure 1: (a) The sampled STPs in England and the daily volume of sewage treated 
plotted on a population density map from census survey 2011. (b) River Ribble 
catchment sampling locations. 
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Figure 2: Summary showing the strength of the difference in CP concentration in the 
influent vs. effluent wastewaters for different samples. (a) Includes data from all STPs 
(n=16) in the study. (b) Includes data from STPs (n= 10) that utilise both secondary 
and tertiary treatments.  
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Figure 3: Environmental loads (mg per day) of CP within the Ribble catchment for 
influent, effluent and river water samples where (a) shows the River Calder flowing 
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0.63 Nitrogen mustard 
alkylating agent; 
attaches to the 
guanine base of 
DNA. Used to 
treat lymphomas, 









0.86 Nitrogen mustard 
alkylating agent; 
used in a variety 
of cancers.  
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Table S5: Calibration ranges 
CP ng/L 
(pg/µL) 
IF  ng/L (pg/µL) 
L1 0.22 0.14 
L2 0.43 0.28 
L3 0.86 0.55 
L4 1.72 1.11 
L5 3.44 2.21 
L6 5.16 3.32 
L7 10.33 6.63 
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Table S6: MS-MS Ion source parameters 
Parameter HESI 
Polarity Positive 
Spray voltage (V) 3000 
Vaporiser temperature (°C) 350 
Sheath gas pressure (arbitrary 
units) 
30 
Ion sweep gas pressure (arbitrary 
units) 
0 
Auxiliary gas pressure (arbitrary 
units) 
30 
Ion transfer capillary temperature 
(°C) 
300 
Collision gas pressure (mTorr) 1 
Skimmer offset voltage (V) -5
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Abstract 
The fate and removal efficiency of cyclophosphamide (CP) and ifosfamide (IF) were 
investigated in two conventional sewage treatment plants (STP-S and STP-C) in 
North West (NW) England during different stages of wastewater treatment. Overall 
average concentrations of CP were 1.17±1.00 ng/L (n=32) in the two plants, which is 
lower than recent measurements conducted elsewhere. Whereas IF was below MDLs 
in both plants. Grab-samples were coordinated with the hydraulic residence time of 
wastewater in each of the treatment stages in order to monitor changes in CP 
concentrations in the same parcel of water as it passed through the STP. Interestingly, 
concentrations of CP were observed to increase from raw influent to final tertiary-
treated effluent and this is likely to be attributable to the degradation of a CP-
metabolite and subsequent ‘liberation’ of the parent CP as the metabolite passes 
through the various sewage treatment processes. This observation, apparent in both 
studied STPs, has implications for chemical fate modelling of anti-cancer drugs, 
especially if STP influent loads are used to predict subsequent fluxes to receiving 
waters rather than final effluent values. Moreover, this increase in concentrations 
made a mass balance difficult to achieve, but highlighted that elimination/removal of 
CP in wastewater during primary to tertiary processing is very low (<20%). The 
calculated fluxes of CP with final effluent discharge were 3.16- 6.48 g/year for STP-S 
and 4.56 -51.57 g/year for STP-C and this highlights that STPs are a continuing 
source of highly water-soluble, recalcitrant anticancer drugs to the environment.  
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1. Introduction
Pharmaceuticals chlorophenoxyisobutyrate and salicylic acid (metabolites of 
clofibrate and aspirin) were first detected in the aquatic environment by gas 
chromatography-mass spectrometry (GC-MS) in the effluent wastewaters of a sewage 
treatment plant (STP) in Kansas City, Missouri (1977) (Hignite and Azarnoff, 1977). 
Since then detection of ‘down the drain’ pharmaceuticals that reach the environment 
and have environmental significance have been increasingly reported in STP effluents 
(Andreozzi et al., 2003, Nefau et al., 2013, Kumar et al., 2012).  
Anticancer drugs are used in medical oncology as a method of treating a range of 
cancers, where one or more agents are given as part of a standardized chemotherapy 
regime. An aging population has seen an increase in their consumption, where they 
are administered during chemotherapy with a curative intent, or in an aim to prolong 
life and reduce patients’ symptoms (Johnson et al., 2008, Booker et al., 2014, Besse et 
al., 2012). Cyclophosphamide (CP) and Ifosfamide (IF) are widely used traditional 
anticancer agents in the UK, as well as other European countries and have aroused 
concern within the scientific and regulatory community with respect to their 
environmental release and potential hazards due to their low dose cytotoxic effects 
(Booker et al., 2014). Particular concern has arisen due to the persistence of some of 
these chemicals and the risk they pose to drinking water, particularly where river 
water is abstracted downstream of STPs for water treatment and a potable water 
supply  (Johnson et al., 2008). Chronic ecotoxicity is infrequently reported for 
anticancer drugs, but where literature is found the concentrations of chronic toxicity 
occurs at more environmentally relevant concentrations (ng/L rather than mg/L) 
(Parrella et al., 2014). Some anticancer agents have been found to exhibit low toxicity 
in standard eco-toxicity tests with aquatic organisms (e.g. 5-fluorouracil has an EC50
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value of 0.11 mg/L for a species of algae (Pseudokirchneriella subcapitata) 
(Zounkova et al., 2010) and methotrexate has an EC50 of 0.015 mg/L for the African 
clawed frog (Xenopus laevis) with similar values reported for fish (B. Rerio) (Bantle 
et al., 1996, Henschel et al., 1997)), but in real aquatic environments that receive 
wastewater effluents anticancer drugs will appear as mixtures alongside metabolites, 
transformation products and other pharmaceuticals and it’s possible that some of these 
chemicals will act synergistically with effects (Parrella et al., 2014).  
 The fate of anticancer drugs during wastewater treatment processes has not been 
studied and yet is likely to provide insight into how some of these chemicals can carry 
over to final effluent, be degraded during secondary treatment processes or lost with 
sewage sludge. Sewage treatment plants (STPs) are designed to reduce the load of 
organic material and pathogens present in raw wastewater; however, they are not 
designed to specifically remove pharmaceuticals or other organic pollutants (Joss et 
al., 2005). Most STPs involve physical-chemical mechanisms of treatment (e.g. 
flocculation and activated carbon adsorption); however this only provides marginal 
removal of some pharmaceuticals (Suarez et al., 2009) with biological methods 
known to provide the most effective elimination for pharmaceuticals.  For example, 
aerobic activated sludge (AS) with long hydraulic retention time (HRT) is a frequent 
treatment option (Oz et al., 2004) and is the most widely used in sewage treatment 
processes across Europe. However, sorption onto the bio-sludge and biodegradation 
under aerobic conditions results in < 2% removal for CP and IF (Booker et al., 2014). 
Therefore, CP and IF degrade very slowly, with little if any degradation occurring 
during the whole sewage treatment process. Previous literature shows that little is 
known about the fate of these chemicals in STPs, with most studies relying on 
estimates from modelling programmes, such as EPISUITE (Dong et al., 2013). 
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Indeed, very low (bio)degradation of CP and IF was demonstrated in effluent samples 
incubated in the dark for 28 days, resulting in experimental half lives of 495 and 577 
days, respectively (Llewellyn et al., 2011). The long half-lives and low degradation 
rates highlight that CP and IF are persistent in STPs and receiving waters.  
The occurrence of CP and IF in STPs has been reported in a number of studies in 
different countries (Buerge et al., 2006, Garcia-Ac et al., 2009, Castiglioni et al., 
2005, Gómez-Canela et al., 2012, Martín et al., 2011), however these studies show a 
lack of information about the removal efficiency and release of CP and IF in STP 
effluents.  Few (if any) studies have considered the fate and distribution of anticancer 
drugs throughout each separate stage of the sewage treatment process in order to 
comprehensively evaluate the biodegradation, persistence and partitioning behaviour 
in both aqueous and solid phases (Llewellyn et al., 2011). Using flow rates and 
measured concentrations at each phase of the sewage treatment process the aim of this 
study was to determine the fate and fluxes of CP and IF from raw influent to final 
treated effluent in two different STPs.  More specifically, the major objectives of this 
study were to (1) evaluate the removal efficiencies of CP and IF in two major STPs, 
(2) compare the capabilities of the two STPs in removing CP and IF, at each stage of
treatment and (3) characterize the profile of CP and IF by quantifying its percentage 
removal throughout sewage treatment.  
2. Materials and methods
2.1. Site description and treatment plant operation 
Two STPs located in NW England were selected for this study; one located near the 
city of Lancaster (STP-S) of 32 - 72.5 ML/day (1 ML = 103 m3) capacity (maximum 
flow to full treatment capacity = 87 ML/day) and the other near the city of Preston 
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(STP-C) receiving 104 ML/day capacity (maximum flow to full treatment capacity = 
234ML/day). Arial photographs of both sites and their systems in place are shown in 
Figure 1 and their main operational and design parameters of the full scale STP are 
summarized in Tables 1 and 2.  In both STPs, sewage from smaller towns reach the 
STPs after multistage pumping because of the distance and flat topography of these 
cities; wastewater enters the works through pumping stations whereas at the treatment 
sites wastewater flow is maintained by gravity. Following gravitational primary 
treatment, the settled sewage effluent is introduced into aeration lanes (STP-S) or 
tanks (STP-C) (activated sludge) for secondary treatment. After settling the effluent 
undergoes a tertiary treatment phase (final settling tanks), before the effluent is 
subjected to UV-light and released into tidal storage tanks (STP-S) or into the nearby 
recipient river estuary (STP-C).  
Plant 1; STP-S serves a population equivalent of 27,698 and receives hospital waste 
from the oncology unit at Royal Lancaster Infirmary (population served =363,000). 
Royal Lancaster Infirmary provides CP and IF as part of their chemotherapy regimens 
and is consumed within this hospital trust at 1300 g/year and 150 g/year, respectively. 
Plant 2; STP-C serves a population equivalent of 247,000 and receives hospital waste 
from the oncology unit located within Royal Preston Hospital (population served = 
390,000). Royal Preston Hospital (Rosemere cancer foundation) provides only CP as 
part of its chemotherapy regimens and is consumed at approximately 610 g/year. A 
neighbouring hospital that serves a population of 330,000 may also contribute to the 
CP load in STP-C as patients attend outpatient clinics and disperse home after 
treatment. Only CP is consumed within this hospital at approximately 1900 g/year. 
The hospitals within the catchments areas for both the STPs investigated rarely use IF 
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as part of their chemotherapy regimen and therefore its presence in the environment is 
expected to be negligible for this specific region of the UK.  
2.2. Sample collection  
The sampling programme was designed so that wastewater samples were collected to 
reflect the HRT within each of the STPs. Samples of raw influent and subsequent 
samples following primary, secondary, tertiary treatment and final effluent, therefore 
reflected the same parcel of water, where possible, as it progressed through the 
treatment plant. Table 2 presents the flow characteristics and HRT for each of the 
major components of the respective plants. 
Samples in STP-S were collected in October 2013, with grab sampling conducted on 
8th October 2013 and 24-hr composite samples collected over a period of seven days 
from 22nd to 28th October 2013.  24-hr composite samples were collected from three 
sampling points, using fixed sampling units; (a) ‘raw’ influent (i.e. crude sewage) (b) 
Mid-treatment (Primary effluent) and (c) Pre-UV treatment. STP-S details are 
presented in Table 1. Grab samples were collected from six sampling points: (a) 
Influent was taken as a mixture of multiple grab samples after preliminary treatment 
(i.e. screening and grit removal); (b) Primary effluent; (c) Aeration effluent; (d) Pre-
UV treatment; (e) Post-UV treatment and (f) Storm return. The daily flow rate at the 
time of grab sampling was 72.5 ML/day and is representative of high flow in this 
plant, with a treatment HRT of 7 hours from raw influent to final effluent. Grab 
sampling details are presented in Table 2.  
Samples in STP-C were collected in November 2014; grab sampling was conducted 
on 18th to 19th November 2014 with the first influent sample collected at 10am. Grab 
samples were collected from five sampling points: (a) influent (crude sewage) was 
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taken as a mixture of multiple grabs after the preliminary treatment (screening and 
grit removal); (b) Primary effluent; (c) Aeration effluent; (d) Pre-UV treatment and 
(e) Post-UV treatment. The daily flow rate during the sampling was 104 ML/day and
is representative of low flow (dry weather) in this plant, with a treatment retention 
time of 25 hours from raw influent to final effluent. Due to the retention on the day of 
sampling, the samples obtained from the aeration effluent were representative of 
influent entering the plant at 4pm on 18th November 2014, and therefore the 
concentrations detected in these samples were disregarded in this study. Grab 
sampling details are presented in Table 2. 
All wastewater samples were collected in 2.5L methanol rinsed amber glass bottles. 
All samples were transported immediately to the laboratory and stored in a dark room 
at 4°C as described by (Llewellyn et al., 2011).  
2.3. Analytical methods 
CP and IF were measured in samples of sewage wastewaters as described in a 
previously published method (Llewellyn et al., 2011). CP and IF in wastewater 
samples were extracted by a two-step solid phase extraction (SPE) technique. This 
involved a pre-concentration step using 500mg Strata-X SPE cartridges 
(Phenomenex, Macclesfield; UK) followed by elution through 200mg of Florisil 
(Biotage, Uppsala; Sweden) using ethyl acetate and ethyl acetate with 10% methanol, 
respectively. The resulting eluent concentrated under N2 and made upto 500 µL with 
the LC mobile phase (comprising ~95% water, ~5% methanol ~0.1% formic acid) and
quantitatively transferred to 2 mL autosampler vials for analysis. Analyte separation 
(10µL inj. volume) was performed on a packed µPLC Hypersil GOLD C18 column 
(50 x 2.1 mm 1.9 µm) using a H2O:MeOH mobile phase gradient. Analysis was 
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performed by liquid chromatography coupled to a triple quadrupole ‘Quantum Ultra 
TSQ’ mass spectrometer (Thermo Fisher Scientific, Hemel Hempstead; UK) 
interfaced with an ion max electrospray ionisation (ESI) and operated with Xcalibur 
software ™ (V.2.0.7.). In this study all CP and IF concentrations are reported in ng/L. 
Chromatograms were integrated using ICIS algorithm of Xcalibur™ 2.0.7 by Thermo 
Fisher Scientific and a linear analyte calibration curve was generated using 1/X 
weighing for six calibration standards each with a constant (5 µg/L) concentration of 
the internal standard (d4-CP). For each analysis sequence the calibration standards 
were bracketed around upto eight unknown samples with mobile phase blanks 
performed within the bracket to check for the carryover and the purity of the internal 
standard (IS).  The system was initially cleaned with pure MeOH prior to each 
analytical run and calculations were performed using area ratios for both CP and IF to 
give recovery values of the IS. MDLs for CP ranged between 0.03 - 0.12 ng/L, and 
between 0.05 - 0.09 ng/L for IF.  
2.4. Mass balance calculations 
The average mass flux (F (g/year)) of CP and IF was calculated by multiplying the 
average aqueous concentrations (CS (ng/L)) with the corresponding average daily flow 
(QS (L/day)). The equation can be expressed as: 
Eqn. 1 𝐹 = 𝑄! 𝑥 𝐶! 
3. Results and discussion
3.1. Concentrations of CP and IF 
A summary of measured CP concentrations is provided in Table 3. 
Cyclophosphamide was detected and quantified in the majority of samples, whereas 
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IF remained below MDLs at both STPs. For CP, concentrations fell below MDL for 
raw influent grab samples collected during dry weather flow at STP-C, with the 
highest concentrations being observed in raw influent 24-hr composite samples at 
STP-S during a period of low flow. Daily 24-hr composite samples were obtained 
from STP-S over the course of a week and showed only moderate day-to-day 
variation in their concentrations of CP, IF was not detectable above the MDL (0.09 
ng/L). CP was detectable in all 21 samples above the MDL (0.12 ng/L). The influent 
samples showed concentrations ranging between 0.14 to 4.31±0.04 ng/L (mean 
concentration = 1.56±1.31 ng/L). The primary effluent samples showed 
concentrations ranging between 0.30±0.06 to 3.52±0.21 ng/L (mean concentration 
=1.61±1.08 ng/L). The final effluent wastewaters after UV treatment showed 
concentrations ranging between 0.88±0.08 – 2.09±0.05 ng/L (mean concentration = 
1.49±0.64 ng/L). Results are illustrated in Figure 2 and Table 3.  
It is well established in the literature that STPs are the most important contributor of 
anticancer drugs to the environment (Buerge et al., 2006, Thomas et al., 2007, Martín 
et al., 2011, Llewellyn et al., 2011, Kümmerer et al., 1997). The two studied STPs 
(STP-S and STP-C) receive domestic, hospital and industrial wastewaters and 
effluents containing the anticancer drug CP in ng/L levels. In general, the detected 
concentrations of CP measured in the influent and effluent were lower than those 
previously reported at a number of STPs in England (Booker et al., 2014). For this 
study, many of the samples were collected as composite samples over a 24 hr period 
and as such displayed a narrower range in concentration, with a lower variation 
compared to grab samples. The 24-hr composite samples did not show any significant 
loss of CP during STP treatment processes. The changes in concentration from the 
influent to the final effluent in this study were not statistically different when a 
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comparison was made between the treatment stages (influent, after primary treatment, 
post-UV). However, the influent composite samples (collected over 24 hr periods) do 
not represent the same wastewater that was sampled in the final effluent.  
For many STPs serving urban catchments their morning and early evening raw 
influent flow rates (under typical low flow conditions) are higher than other periods of 
the day. It is plausible that the level of human pharmaceuticals present in raw influent 
would also be higher during this morning ‘flush’.  Therefore, to determine the fate of 
CP between the different processing stages and to attempt a mass balance over a 
relatively short time scale (<24 hr), then grab-sample data were used, these data relate 
to the same parcel of water passing through the respective STPs and are based on the 
HRTs for the sampling periods shown in Table 2.  
Table 4 reports the output loads for STP-S as mean CP values (mg/d). The quantities 
of CP discharged into the environment are calculated by multiplying the average 
concentration by an average daily flow rate (range 32 - 36 ML/day), reported in Table 
4. The total amount of CP discharged by STP-S with final effluent exceeds 18±8
g/year. 
3.2. Mass balance for CP in STPs operating tertiary treatment  
As described above grab samples were collected at carefully assessed time intervals 
(calculated from ancillary data shown in Table 2) to allow sampling of the same 
influent water as it progressed its way through the respective STP. Results from grab 
sampling for STP-S and STP-C are summarised in Figure 3a and 3b, respectively, 
with the box plot showing the range of concentrations (ng/L) of CP for each step 
sampled in the treatment process. The relative standard deviations (RSD%s) for CP 
detected in the sewage works by grab sampling were between 3 and 20% for STP-S 
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and between 11 and 13% for STP-C. Six measurements are given for STP-S (Figure 
3a) and CP increases within the plant from 0.12 ng/L in the influent (RSD = 4%) to 
0.18 ng/L post-UV treatment (RSD = 20%). Five measured values are provided for 
STP-C (Figure 3b) and again CP increases from being < MDL in the raw influent to 
1.36ng/L being released post-UV treatment (RSD =13%). Results from grab sampling 
for STP-S and STP-C are presented as environmental loads (g/year) in Table 4. As CP 
passes through the STPs there is a notable increase in the concentrations and hence 
flux of the chemical in both treatment plants. Previous studies have shown that the 
elimination of CP in STPs is not fully removed from the wastewater during treatment 
processes (Buerge et al., 2006, Thomas et al., 2007, Martín et al., 2011, Llewellyn et 
al., 2011). The majority of studies reporting CP in STP wastewater show 
concentrations ranging from e.g. > MDL-43.8 ng/L with similar concentrations 
observed between the influent (median = 5.8 ng/L) and final effluent (median =6.3 
ng/L), with comparable results for IF (Negreira et al., 2014, Zhang et al., 2013). 
However, several studies do show increases in the effluent concentration of CP, 
although this observation was not acknowledged, possibly due to sampling 
limitations, whereby there was a disconnect between the raw influent and the final 
effluent with different water parcels sampled (Buerge et al., 2006, Llewellyn et al., 
2011). To our knowledge this study is the first study to examine concentrations of CP 
in the same parcel of wastewater as it passes through the various stages of treatment.  
From Figure 3 there is a clear increase in CP concentrations moving from primary 
treatment to final post-UV effluents at both STP-S and STP-C. While the 
concentrations are not high at both plants relative to earlier studies this increase is 
statistically significant. The results here suggest that a proportion of CP is entering the 
STP in raw influent in a conjugated or bound form which is not detected using our 
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current analytical methodology (detailed above). As CP progresses through the 
treatment steps, then more of the CP is ‘liberated’ and is detectable.  There is potential 
for CP reactivation from its subsequent conjugate during treatment leading to an 
increase in levels relative to the influent wastewaters (Kumar et al., 2012). 
Glucuronide and sulphate conjugates are phase II metabolites that leave the 
biologically active moiety of the parent drug intact, this phenomenon has been 
observed for other pharmaceuticals (Khan and Ongerth, 2004). For example, the rapid 
hydrolysis of paracetamol glucuronide has been observed in batch scale sewage 
investigation (Khan and Ongerth, 2004). The effect of this phenomenon is that studies 
using influent concentrations only are likely to underestimate the quantity of CP 
within the STP and its subsequent release into surface waters with final effluent. This 
also has the effect of confounding a mass balance approach. For example, the removal 
efficiency is effectively reversed, whereby CP is formed within the plant, rather than 
removed/eliminated. For example, taking the data as they are and assuming liberation 
or reactivation of CP from a bound or conjugated form (most notably after primary 
and then secondary treatment – see Figure 3) then there is no removal of the CP 
within the STP and a mass balance is not achieved with formation of CP within the 
STP (147±24% for STP-S and 1131±152% for STP-C).  
CP was measured above the LOD in raw influent entering STP-S, but was not 
measured (below LOD) in influent entering STP-C, therefore the LOD was used at 
0.12 ng/L to generate an annual input flux of 4.56 g/year when calculating the 
elimination efficiency. The HRT during the treatment at STP-S on the day of 
sampling was 7.14 hr and the HRT for STP-C on the day of sampling was 25.6 hr 
(almost 4 fold longer than STP-S). The difference in CP concentrations between STP-
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S and STP-C may be related to the drug consumption and hospital proximity rather 
than their elimination efficiencies. (Llewellyn et al., 2011).  
The HRT of wastewater in primary treatment was 2.69 hr for STP-S and 3.43 hr for 
STP-C. In both cases primary treatment resulted in extensive reactivation of CP. This 
is illustrated in Figure 3 and demonstrated in Figure 4 especially apparent STP-C 
where no CP was detectable in the influent, but after a HRT of 3.43 hours in the 
primary settling tanks CP was detectable with an average concentration of 0.27±0.03 
ng/L (10.24±1.15 g/year is detectable). Both STP-S and STP-C utilise similar 
processes for their primary treatment. For CP, removal is not apparent during primary 
treatment with evidence suggesting that CP is ‘reactivated’ during wastewater 
retention in the settling tanks. A similar result has been demonstrated for oestrogens 
where an absence of removal was also noted during primary treatment (Gabet-Giraud 
et al., 2010). During primary treatment flocculation processes enhance the removal of 
suspended solids, thus allowing the settling and hence removal of particle-bound 
chemicals from the water body. Carbamazepine and ibuprofen with log Kow in the 
range of 2.4-5.3 were not affected by coagulation/flocculation and settling of 
particulate matter and hence no removal was seen for these compounds (Carballa et 
al., 2005). A similar process is expected for CP which possesses a much lower Kow 
(log Kow = 0.63) with a high aqueous solubility and hence is unlikely to be lost 
through particle settling during primary treatment (Booker et al., 2014). Literature on 
the removal of pharmaceuticals by sedimentation processes is scarce, and data are 
often related to more than one treatment method (activated sludge) (Khan and 
Ongerth, 2004, Kumar et al., 2012). Removal of CP to sludge during primary 
treatment may occur for its bound or conjugated form, but the evidence here 
demonstrates an increase in CP between raw influent and primary effluent, indicating 
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that CP is liberated or reactivated from a bound/conjugated form.  Secondary 
treatment involves the process of introducing oxygen into primary treated sewage 
combined with organisms to develop a biological flocculation which reduces the 
organic content of the sewage. The removal of CP from the aqueous phase during 
treatment with AS was calculated. In both STP-S and STP-C AS was shown to be 
ineffective as an elimination process for this chemical. A 33.2% increase in mass was 
detected in STP-S, when CP was incubated in the aeration lanes for 1.2 hr. Similarly 
in STP-C during both secondary and tertiary treatment CP increased in mass by 
~475% (Figure 4-b). Previously published studies on pharmaceutical fate during 
incubation with AS show varied results, with some compounds showing no sorption 
onto the sludge/particle matter (e.g. ibuprofen) (Carballa et al., 2005). Other 
compounds that are positively charged (i.e. in an ionised form at neutral pH) can 
show removal due to electrostatic attraction with negatively charged groups at the 
surface of the AS (e.g. diclofenac, (Jelic et al., 2011)). However CP and IF are not 
ionisable (Booker et al., 2014) and thus removal is unlikely via this route.  
The removal during tertiary treatment was evaluated for STP-S, with  surface sorption 
to the low particle content of this effluent considered negligible (Gabet-Giraud et al., 
2010). Figure 4-a reveals that during tertiary treatment CP is not degraded/removed, 
but neither is it reactivated from a conjugated form of CP (i.e. concentrations do not 
increase). Of the different treatment stages in STP-S, the tertiary treatment has the 
longest HRT (3.20 hr). In both STP-S and STP-C there is a final treatment process 
(UV) in operation. The results here demonstrate that this is the most effective stage of 
treatment for removing CP; however 80.8% of the CP still persists between the pre-
UV and post-UV samples in STP-S. For STP-C, the UV treatment doesn’t appear to 
have an effect on CP concentrations (see Figure 4b). Exposure of aqueous CP to UV 
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light is not considered to be a significant loss pathway, as the persistence of CP and IF 
was confirmed  when exposed to UV treatment through irradiated lake water 
experiments (with a proposed half-life of 44 days for CP) (Buerge et al., 2006). 
Advanced oxidation processes (e.g. UV in the presence of H2O2) can provide a 
significant degradation route for CP (Franquet-Greil et al, 2015 – SETAC  Barcelona, 
2015 poster). 
Elimination of CP during waste water treatment processes is very poor with final 
treated effluent concentrations of CP for both STPs frequently greater than the 
concentrations in raw influent. Poor STP elimination of this drug has been reported by 
others (Buerge et al., 2006, Thomas et al., 2007, Martín et al., 2011, Llewellyn et al., 
2011). Effluent concentrations greater than those observed for the influent may be 
explained by the presence of a CP metabolite (possibly a conjugate) that is 
subsequently transformed by biotic and/or abiotic processes, particularly during 
primary treatment into the parent chemical. Similar to oestrogens, CP has the 
potential to occur as a glucuronide conjugate in sewage influent that could 
presumably, be cleaved in sewage, thus increasing its environmental concentration 
(Kumar et al., 2012). Because these conjugates were not included in the analysis, no 
firm conclusion can be made about their biotransformation. However it is apparent 
that CP (a compound with low adsorption coefficient) remains in the aqueous phase 
which favours their mobility through the STP and into receiving waters (Kosjek and 
Heath, 2011). 
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Table 1:  Flow characteristics of STP-S and STP-C 
STP-S STP-C 
Dry weather flow 30 ML/day 190 ML/day 
Max Flow to full treatment 87 ML/day 234 ML/day 
Average Flow 35 ML/day 101 ML/day 
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Table 2: Flow characteristics and HRTs (Hydraulic retention time) for STP-S and 
STP-C during grab sampling campaigns 
STP-S STP-C 
Flow to full treatment (ML/day) 72.5 104 
Primary tank volume each (m3) 2708 2124 
No of tanks in use 3 7 
Primary tank retention time (h) 2.69 3.43 
Secondary Aeration tank volume 
(m3) 
3750 49000 
Aeration tank retention time (h) 1.24 11.31 
Tertiary Final tank volume each 
(m3) 
2420 5897 
No of tanks in use 4 8 
Final tank retention time (h) 3.20 10.89 
Retention time in plant 7.14 25.63 
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Table 3: Summary of 24-h composite samples and grab samples for CP at STP-S and 
STP-C, demonstrated as concentrations in ng/L. Standard deviated is shown where n 
> 2.
Treatment stage STP-S (ng/L) STP-C (ng/L) 
Storm return 0.25±0.03 NA 
Raw Influent 0.12 – 4.31±0.04 NF 






Pre-UV 0.22±0.02 1.28±0.14 
Post-UV 0.18±0.04 – 
2.36±0.01 
1.36±0.18 
NA – Not applicable 
NF – Not found  
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Table 4: Calculated flux (mg/day) of CP at STP-S using 24-h composite sampling. 







Mass load (mg/day) detected at each step Mass in 
effluent 
(%) 








69.42 (5.09) 32.19 (0.05) 57.37 
Tue 
23/10/2012 
36 39.49 (1.58) 78.55 75.29 (1.96) 190.66 
Wednesday 
24/10/2012 
35 38.43 (2.38) 43.89 (0.40) 70.72 (3.14) 184.09 
Thursday 
25/10/2012 
34 36.35 29.78 (1.20) 34.63 (4.50) 95.28 
Friday 
26/10/2012 







70.80 (0.17) 54.82 
Sunday 
28/10/2012 
33 4.55 9.90 (1.87) 33.78 (3.06) 741.67 




49.47 (21.45) 98.20 
Mass flux (mg/day) was calculated according to Eqn 1 
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Table 5: Calculated mass load (g/year) of CP at STP-S and STP-C during grab 
































18th to 19th 
November 
2014 






* Sample was obtained at random (not collected at the correct time interval with the
respect to the HRT and therefore represents a different water parcel)
NA – Not applicable
NF – Not found
Paper III - 25
 
 





Paper III - 26
 
 
Figure 2: CP concentrations (ng/L) in the influent, primary effluent (after primary 
treatment) and post UV effluent wastewaters for 24-hr composite samples taken over 
a 7 day period.  
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Figure 3: Box plot summary of CP concentrations (ng/L) in (a) STP-S (Stodday) and 
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Figure 4: Schematic of (a) STP-S and (b) STP-C showing their treatment facilities and 
their calculated removal efficiencies for CP. Highlighted boxes (SAMPLE) show the 
sampling locations along the STPs 
(a) 
(b)
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Abstract 
The regional consumption of anticancer drugs in the Aire catchment (NE England) 
and their subsequent fate in the aquatic environment was investigated using a 
catchment based water-quality model and accompanied by river water measurements. 
A shortlist of 10 priority drugs with population-based consumption data were used as 
input to a GIS-based water quality model (LF2000-WQX). Predicted environmental 
concentrations along the Aire and Calder rivers were generated with modelled 
concentrations compared to measured concentrations for two of these chemicals; CP 
and IF. The measured environmental concentrations (MECs) of CP ranged from 0.17 
to 4.53 ng/L (average 1.14 ng/L) whereas IF showed lower concentrations ranging 
from <LOD to 1.82 ng/L (average 0.51 ng/L) and was not as frequently detected as 
CP. Comparison of modelled to measured river concentrations were generally good, 
although for the River Aire the MECs of CP were ~2.5-fold higher than PECs after 
the major conurbation of Leeds, ~65 km downstream from the first sampling point. 
Better agreement was observed on the River Calder, although the effect of specific 
STPs greatly elevated MECs above PECs for certain locations, yet a spike in 
concentration is observed at the lower end of the Calder that occurs in a reach that 
does not have a close upstream STP.  Reasons for discrepancies between modelled 
and measured data are discussed. Risk quotients – the ratios of PECs to predicted no-
effect concentrations (PNECs) derived largely from Daphnia magna toxicity assays 
were all <1 in this study, indicating that the risk of acute toxicity to sentinel aquatic 
invertebrates through exposure to common-use anticancer drugs is low.   
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1. Introduction
Cyclophosphamide (CP) and ifosfamide (IF) are two widely used alkylating agents 
belonging to the specialised class of anticancer drugs, the nitrogen mustard analogues 
(categorised as L01AA under the Anatomical Therapeutic Chemical (ATC) 
Classification system), used in chemotherapy as a treatment to a variety of cancers 
(Booker, Halsall et al. 2014).  
In France a marked rise in the use of anticancer drugs has been demonstrated between 
2004 and 2008, where CP consumption has increased by 8.5%, subsequently leading 
to higher environmental levels (Besse, Latour et al. 2012). The mean European 
consumption of CP is 10.4 µg/capita/day (Johnson, Oldenkamp et al. 2013), with 
France and the UK having approximate consumptions of 13.01 and 39.50 
µg/capita/day, respectively. IF consumption is lower, with a UK consumption 
estimated to be 0.65 µg/capita/day whereas in France this is estimated to be 4.4 
µg/capita/day in the UK (Besse, Latour et al. 2012; Booker, Halsall et al. 2014). 
Regional discrepancies in consumption of the anticancer drug fluctuate, with the 
River Aire catchment consuming only 2 µg/capita/day of CP and 2 µg/capita/day of 
IF (calculated from regional hospital data). Whilst the consumption of this specialised 
class of pharmaceuticals is much lower than for commonly prescribed or ‘over the 
counter drugs’, such as codeine (308.23 µg/capita/day in the UK) (Baker, Barron et 
al. 2014) their high toxicity gives reason for concern. Anticancer drugs have a high 
pharmacological potency and are designed to halt cell division and induce subtle 
genetic changes at low doses, making them increasingly targeted in environmental 
monitoring and risk assessment programmes (Johnson, Jürgens et al. 2008; Ferrando-
Climent, Rodriguez-Mozaz et al. 2014). 
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The growing consumption of anticancer drugs suggests that concentrations in 
wastewater, final effluents and river water may increase, although this will be 
dependent on  local/regional consumption, sewage treatment processes  and river 
water flow and dilution (Booker, Halsall et al.). To date there are relatively few data 
on the occurrence of anticancer drugs such as CP and IF in surface waters and this 
remains a handicap for undertaking thorough risk assessments.  Analytical 
improvements (e.g. MDLs ranging from ~10 ng/L in 1998 to < 1 ng/L in 2011) with 
liquid chromatography tandem mass spectrometry (LC-MS/MS) have led to a number 
of these chemicals being reported in hospital waste effluents, sewage treatment plant 
(STP) wastewaters and river waters in an increasing number of studies (Castiglioni, 
Bagnati et al. 2005; Buerge, Buser et al. 2006; Garcia-Ac, Segura et al. 2009; Yin, 
Shao et al. 2010; Llewellyn, Lloyd et al. 2011; Martín, Camacho-Muñoz et al. 2011).  
Understanding the processes that determine the fate of CP and IF in the aquatic 
environment are crucial for predicting environmental concentrations at the whole 
catchment scale but rely on accurate hydrological data, pharmaceutical  consumption 
data and knowledge of the chemical fate processes within STPs. Water quality and 
exposure models such as the GREAT-ER (Geography referenced Regional Exposure 
Assessment Tool for European Rivers) and LF2000-WQX (Low Flow 2000 – Water 
Quality Exposure) have been used to successfully to predict environmental 
concentrations (PEC) for a variety of organic contaminants in river systems (Boeije, 
Vanrolleghem et al. 1997; Feijtel, Boeije et al. 1997; Williams, Johnson et al. 2003; 
Williams, Churchley et al. 2012). However, few studies ‘ground truth’ modelled PEC 
with a coordinated measurement campaign to verify modelled results. This is 
important as variations in chemical emissions both spatially and temporally, as well as 
varying hydrology and un-quantified chemical fate processes may result in 
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discrepancies between predicted and observed behaviour for the contaminant in 
question (Sabaliunas, Webb et al. 2003). Authenticity of models may be 
accomplished via the use of measured environmental data.  
The aim of this study was to use the catchment chemical fate model (LF2000 –WQX) 
to predict environmental river water concentrations for a selection of common-use 
anticancer drugs and compare these predictions to measured environmental 
concentrations for two of these chemicals.  Two rivers, the Aire and Calder, were 
selected based on previous chemical fate studies (Schowanek and Webb 2002) with 
both arising in sparsely populated uplands with lower reaches passing through heavily 
urbanized areas served by a variety of sewage treatment plants (STPs) that discharge 
treated effluent (the source of anticancer drugs) into the rivers.  
2. Methods
2.1. Study area and sampling 
In this study, fourteen sampling locations were selected along the River Aire 
(catchment area approximately 282 km2), which measures 115 km in length and is a 
major river in Yorkshire (UK). The Aire rises at Malham Tarn and flows through 
West Yorkshire to Gargave (population 1,764), Skipton (population 14,313), 
Keighley (population 89,870), Bingley (population 19,884), Shipley (population 
28,162), Leeds (population 757,700), Swillington (population 3,530) and 
Woodlesford (population 21,010). Castleford (population 39,192) is the confluence of 
the Aire and Calder. 
Eleven sampling locations were selected along the River Calder (catchment area 
approximately 341km2), which measures 72 km in length and is a major tributary 
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river that rises on the eastern slopes of the Pennines and flows through the large urban 
and rural borough before joining the River Aire at Castleford. The Calder flows 
through villages, as well as the large towns of Brighouse (population 32,360), 
Mirfield (population 18,621), Dewsbury (population 62,945) and Wakefield 
(population 76,886). Sampling locations are shown for both the River Aire and Calder 
in Figure 1, including the STPs located along the catchment.  
Two sampling campaigns were conducted with river water collected by grab sampling 
on consecutive days in April 2013 (30.04.2013 to 01.05.2013) and July 2013 
(24.07.2013 to 25.07.2013). Sampling locations targeted upstream and downstream of 
the major STPs and near the confluence of the River Aire and Calder, the only 
exception is sampling point A7 (STP-1) which is a sampled STP effluent discharge 
stream on the River Aire. Duplicate samples were collected in 2.5L amber glass 
bottles (pre-washed and methanol rinsed), on return to the lab all samples (500mL) 
were filtered with GF/F filter paper (Whatman, UK), spiked with 5µL of deuterated-
cyclophosphamide (d4-CP) internal standard (IS) for quantification purposes and 
stored at 4°C.  
Precipitation in the week before sampling in April 2013 was low at 10.6 mm/week 
and 11.3 mm/week in the Aire and Calder catchments, respectively. There was 
minimal precipitation on the days of sampling (30/04/2013 to 01/05/2013). 
Precipitation in the week before sampling in July 2013 was higher at 23.2 mm/week 
and 27.7 mm/week in the Aire and Calder catchments, respectively. Precipitation was 
low on the days of sampling 24-25 July 2013 with rainfall 1.0 mm/day and 5.1 
mm/day, respectively. Data were averaged from five locations in the catchment 
(www.worldweatheronline.com).  
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Gauged flow data are available for the River Aire at Lemonroyd (NGR SE381282) 
and for the River Calder at Methley (NGR SE408257). The daily flow values for the 
sampling days were obtained from the National River Flow Archive (CEH) 
http://www.ceh.ac.uk/data/nrfa/. The flow data were close to the Q95 low flow 
percentiles for the sites based on a 28 year daily flow record. Thus, any 
concentrations reported would represent the highest expected exposures that wildlife 
would experience in these rivers. Hydrological data are provided in Table 1.  
2.2. Sample preparation and chemical analysis 
Chemical standards of cyclophosphamide monohydrate (2-[Bis(2-
chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide) and ifosfamide 
(N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine-2-oxide) were 
obtained from Sigma Aldrich (Gillingham, Dorset, UK). Custom-synthesized internal 
standard (IS) of deuterated-cyclophosphamide (d4-cyclophosphamide or d4-CP) was 
purchased from Qventas Laboratories (Branford, CT, USA), with HPLC-grade 
solvents purchased from Rathburn chemicals (Walkerburn, Scotland). Calibration 
curves were performed at seven levels, ranging from 0.14 to 6.63 ng/L for IF and 
from 0.22 to 10.33 ng/L for CP, in mobile phase (95% water, 5% methanol, 0.1% 
formic acid), each calibrate contained ~5µL IS d4-CP, resulting in a concentration of 
15 ng/L.   
Extraction and analysis of the samples followed a previously described method 
(Llewellyn, Lloyd et al. 2011), where 500mL of filtered (GFF filters, Whatman, UK) 
sample was spiked with 5 µL of d4-CP IS for quantification purposes and extracted 
using Strata X 500mg cartridges (Phenomenex, Macclesfield; UK). After the pre-
concentration step cartridges were dried and eluted with 10 mL of HPLC grade ethyl 
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acetate. The elute was then loaded onto 200 mg Florisil (Biotage, Uppsala; Sweden) 
and eluted with 10% methanol in ethyl acetate, concentrated under N2 and 
reconstituted in 500 µL of mobile phase.  
Analysis was performed with liquid chromatography coupled to a triple quadrupole 
‘Quantum Ultra TSQ’ mass spectrometer (Thermo Fisher Scientific, Hemel 
Hemsptead; UK) interfaced with an ion max electrospray ionisation (ESI) and 
operated with Xcalibur software ™ (V.2.0.7.). Analyte separation (10 µL inj. volume) 
was performed on a µPLC Hypersil GOLD C18 column (50 x 2.1 mm 1.9 µm) using a 
H2O:MeOH mobile phase gradient (Llewellyn, Lloyd et al. 2011). Chromatographic 
peaks were integrated using the ICIS algorithm of Xcalibur™ which was also used to 
generate linear calibration curves using a 1/X weighting. Analyte peak signal to noise 
(S/N-RMS) ratios were obtained with the manual noise region option in Xcalibur™. 
2.3. Hospital consumption  
Table 2 presents consumption data obtained for hospitals within the River Aire and 
Calder catchment (West Yorkshire, Northern England). For this survey two of the 
National Health Service (NHS) trusts within the region were included to calculate 
their annual (kg/year) and per capita consumption (µg/cap/d). The Airedale NHS 
Foundation Trust contains collective information from Airedale general hospital, 
Skipton general hospital and Castleberg hospital, serving a population of 238,503. 
The Leeds teaching hospitals NHS trust contains collective information from Leeds 
general infirmary, St James’ University hospital, Chapel Allerton hospital, Leeds 
Children’s hospital, Seacroft hospital and Wharfedale hospital, serving a population 
of 2,600,000.   
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2.4. Geographic based exposure modelling 
Water quality modelling (Johnson, Jürgens et al. 2008) was conducted using  the GIS-
based water quality model, LF2000-WQX. This can predict river water concentrations 
of ‘down the drain’ chemicals throughout the river network of England and Wales 
using human population data and long-term meteorological records on rainfall and 
runoff (Williams, Keller et al. 2009). The model has been used previously to 
successfully model steroid oestrogens and has been found to give acceptable 
agreement with measurements (Jobling, Williams et al. 2006; Williams, Churchley et 
al. 2012). Concentrations of 10 anticancer drugs were predicted for the Aire and 
Calder catchments using the local consumption data described above as the starting 
point. The model was run using the STP per capita load (after biodegradation) as the 
output value for each individual chemical (Table 2) (sewage effluent value CP = 0.5 
µg/cap/day) with the assumption of no in-stream degradation.  
2.5. Risk assessment  
Finally, using toxicity assay data for key aquatic invertebrates then the low-flow 
model was also used to calculate risk quotients for two of the anticancer drugs along 
the Aire and Calder river basin (Feijtel, Boeije et al. 1997). The risk quotient (RQ) 
was performed to express the risk of the anticancer drugs to the environment. It is 
calculated as a quotient of the predicted environmental concentration (PEC) derived 
from the LF2000-WQX model for imatinib (L01XE01), hydroxycarbamide 
(L01XX05), methotrexate (L01BA01), capecitabine (L01BC06) and fluorouracil 
(L01BC02) with predicted no effect concentrations (PNECs) gleaned from toxicity 
assays. RQ for ifosfamide (L01AA06) and cyclophosphamide (L01AA01) are 
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calculated as a quotient of the measured environmental concentrations (MEC) in the 
River Aire and Calder with results of the PNECs. RQ were calculated according to:  
RQ = PEC
PNEC
=  PEC!"!"/!        (1) 
PNEC can also be estimated as the quotient of the toxicological relevant 
concentration (EC50) and a modifying or safety factor (f = 1000). For this purpose, the 
EC50 for Daphnia associated to the anticancer drugs was used for RQ calculations, 
where values are shown in Table 3. For data interpretation, the maximum probable 
risk for ecological effects from contaminated water was followed (Franquet-Griell, 
Gómez-Canela et al. 2015):  
RQ < 1.0 indicates no significant risk; 
1.0 ≤ RQ < 10 indicates a small potential for adverse effects;  
10 ≤ RQ < 100 indicates significant potential for adverse effects; 
RQ ≥ 100 indicates that potential adverse effects should be expected.  
3. Results and Discussion 
3.1. Priority contaminants derived from regional hospital consumption data 
Table 2 reports the PECs of the ten common-use anticancer drugs in STP effluents 
and river water based on hospital usage data (from NE England), populations they 
serve, mean human excretion rate and potential for drug (bio) degradation during 
sewage treatment processes. Full details of the prioritisation methodology are 
described by Booker et al., 2014. Regional factors, such as variation in consumption 
levels, excretion rates, STP removal rates, size of the receiving water body and limits 
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of detection in analytical procedures can account for differences in the values and 
make predictions of the anticancer drugs difficult. The predicted effluent load 
(µg/cap/d) was used as a parameter for calculating the distributions of concentrations 
for the anticancer drugs using the LF2000-WQX model and mean PECs for the River 
Calder and Aire at the 95th percentile are presented. Local factors, such as variation in 
consumption, STP processes, dilution to the receiving river, analytical method and 
MDLs can all account for differences for MECs and make predictions of the 
anticancer drugs difficult (Toolaram, Kümmerer et al. 2014).  
Based on this assessment anticancer drugs have been prioritised exclusively for this 
river catchment. Imatinib (L01XE01) was the most consumed L01 drug and also the 
compound to have the highest PEC in the effluent (PECeff) and surface waters 
(PECriver). Clinical studies show marginal elimination by urinary excretion (9%) and 
insignificant biodegradation (<1%), yet still resulting in a high PECeff (164.2 ng/L) 
and PECriver (16.4 ng/L). Imatinib has been selected by other prioritisation methods 
(Besse, Latour et al. 2012; Booker, Halsall et al. 2014; Franquet-Griell, Gómez-
Canela et al. 2015), however predicted to be present in effluent at much lower 
concentrations. The high PECeff  is due to a significantly higher consumption (393 
kg/year) compared with the lower consumption found in the NE England (20.4 
kg/year) (Booker, Halsall et al. 2014). Imatinib shows that a higher proportion of the 
parent drug will be released unmetabolised in faeces (20%) and sorption to sludge 
will be a removal factor in STPs that hasn’t been identified, with possibility of 
occurrence in soil, following dispersion of sewage sludge to farmland (Booker, 
Halsall et al. 2014).  
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The second highest calculated PECeff is azacitidine (L01BC07), a compound that has a 
significantly lower consumption than imatinib (15.5 kg/year) but has a high urinary 
excretion rate (68% of the parent chemical) and negligible biodegradation (<1%). 
This compound was not featured in a prioritisation listing (focused on NW England) 
due to its low consumption (0.07 kg/year) (Booker, Halsall et al. 2014), highlighting 
the importance of using regional consumption data when studying a particular 
catchment. Another anticancer agent, capecitabine (L01BC06), a pro-drug that is 
metabolised to 5-fluorouracil (5-FU) (L01BC02) would simply add to the load of 5-
FU present in STPs and hence the average PECs for 5-FU presented in Table 2 is 
likely to be underestimated  
Other compounds included in this study are nilotinib (L01XE08), hydroxycarbamide 
(L01XX05), methotrexate (L01BA01), sunitinib (L01XE04), ifosfamide (L01AA06) 
and cyclophosphamide (L01AA01). Cyclophosphamide is presented with the lowest 
PECeff and PECriver values in Table 2, yet this compound has been previously 
identified in STP effluents and receiving waters at 5.55±4.84 ng/L and 1.36±1.49 
ng/L, respectively (Booker, Halsall et al.). Ifosfamide was not detected in this NW 
England river basin study, probably due to its low consumption (Booker, Halsall et 
al.).  
3.2. Cyclophosphamide and ifosfamide in River Aire and Calder 
CP and IF were detected in 90% and 56% of sampling sites, respectively. Figure 2 
presents the progression of CP along the River Aire (Figure 2-a) and Calder (Figure 
2-b). IF was detected near the river source (average 0.14±0.05 ng/L) at A1 in the 
River Aire in April 2013 and this may be attributed to point runoff associated with a 
household or community septic tanks as a STP is not present in this area.  
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For CP (Figure 2-a) the highest concentration was measured at site A7 (STP-1) 
(average 4.53 ng/L) along the River Aire and C1 (average 1.74 ng/L) along the River 
Calder. CP concentrations ranged from 0.17 to 4.53 ng/L (average 1.14 ng/L) for the 
whole study catchment. The River Aire and Calder CP levels were comparable to 
those reported in a NW England river catchment study (average 1.36 ng/L) (Booker, 
Halsall et al.). Higher concentrations of CP were observed in the River Aire in July 
2013 (average 2.0 ng/L) than for April 2013 (average 1.2 ng/L) despite higher river 
flows that may have had a diluting effect on river concentrations (Table 1). The 
higher concentrations of CP in the River Aire for July stem from sampling point A7 
(STP-1) where a concentration of 6.1 ng/L was measured close to an STP effluent 
discharge point in the city of Leeds (versus 3.0 ng/L in April 2013). From A7 
downstream to A14 concentrations of CP are higher compared to previous 
measurements conducted in April 2013.   
For IF (Figure 2-b) the highest concentration was measured at site A14 (average 1.82 
ng/L) along the River Aire and C8 (average 0.17 ng/L) along the River Calder. MECs 
for IF range from <LOD to 1.82 ng/L (average 0.51 ng/L) for this catchment study. 
The River Aire and Calder IF levels were higher than those reported in NW England 
river catchment study, where IF was <LOD (Booker, Halsall et al.) and this likely 
reflects the higher consumption of IF at the major hospital trusts in the Aire 
catchment (2 µg/cap/day versus 0.65 µg/cap/day in NW England (Booker, Halsall et 
al. 2014)). Higher concentrations of IF are seen in the River Aire in July 2013 from 
A7 (average 1.16 ng/L) than for April 2013 (average 0.6 ng/L) despite having greater 
dilution (Table 1). Similarly to CP, the high MECs for IF start from sampling point 
A7 (STP-1) where 1.76 ng/L of IF was detected at an effluent discharge point in 
Leeds (versus 0.60 ng/L in April 2013) and IF concentrations remain higher at 
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downstream sampling points in the River Aire. It is thought that this higher effluent 
load from Leeds STP could be attributed to an increased daily consumption (possible 
due to an outpatient clinic administering CP and IF). 
In this study, STPs located in more populated areas (Leeds to Castleford), are likely to 
be the most important sources of CP, with the highest measured concentrations 
observed between A7 and A14 on the River Aire and at C6 (Brighouse) on the River 
Calder. The highest MECs for IF were between A13 to A14 (Beal to Chapel 
Haddlesey) on the River Aire and but with much lower levels measured in the River 
Calder.  
3.3. Predicted anticancer concentrations in the Aire and Calder using 
LF2000-WQX 
Predicted imatinib (L01XE01), azacitidine (L01BC07), nilotinib (L01XE08), 
hydroxycarbamide (L01XX05), methotrexate (L01BA01), capecitabine (L01BC06), 
5-fluorouracil (L01BC02), sunitinib (L01XE04), ifosfamide (L01AA06) and
cyclophosphamide (L01AA01) concentrations in the River Aire and Calder were 
generated using LF2000-WQX assuming a predicted per capita STP load after 
excretion and (bio) degradation (as listed in Table 2). PECs and MECs for both CP 
and IF are shown in Figures 1 and 2 along with the mean flow rate calculated from the 
LF2000-WQX model.  
For the River Aire (Figure 1-a) PECs for CP are much lower (by approximately 2.5 
fold) than the values measured in both April and July 2013. In addition, the measured 
concentrations appear to be strongly influenced by inputs from STPs, where a peak in 
concentrations was observed for A7 (STP-1), 65km downstream of Airton. The large 
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increase in river flow (40 m3/sec) some 75 km downstream from Airton represents the 
confluence of the River Calder and River Aire. The modelled data are broadly in 
agreement with the measured data here, with concentrations remaining at ~1 ng/L for 
the remainder of the river length despite the dilution effect of the two rivers merging. 
The increase in concentrations, both predicted and measured some 40 km downstream 
of Airton (the first upstream sampling site) represents an increase of CP due to 
discharge from a large STP (>150,000 population) at Esholt (A5).  The increase in 
concentrations representing the STP effluents at A5 are not present in the IF measured 
data, and the only STP that influences the river water concentrations is A7 (STP-1).  
The River Calder (Figure 2-b) PECs appear to agree with the average MECs, but do 
not capture the localised increase in concentrations associated with inputs from the 
major STPs. For example, 10 km downstream from Widdop a concentration peak is 
observed at Halifax due to a STP serving a population between 100,000 to 150,000. 
Again at 25km another increase is observed due to a large STP (>150,000 population) 
at Brighouse with a further increase in concentrations possibly associated with 
discharges from the Wakefield STP which is not captured by the model.  
Modelling for the eight other priority anticancer drugs was carried out for the River 
Aire and Calder using LF2000-WQX and the average 95th percentile data (ng/L) are 
reported in Table 2. The PECriver are all approximately 2 fold greater than the values 
derived by the initial prioritisation method that assumed a 10-fold dilution from STP 
effluent to receiving waters (Table 2) (Booker, Halsall et al. 2014) . Both CP and IF 
have shown that the modelled data are a good representation of the environmental 
levels, if not a little underestimated and so we can expect the other anticancer agents 
listed to have concentrations similar to these predictions for the River Aire catchment. 
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The predictions could benefit from more accurate (bio) degradation estimates during 
sewage treatment processes.  
3.4. Risk assessment 
The risk assessment of anticancer drugs in the River Aire/Calder catchment was 
performed based on the 95th percentile mean PECriver values generated using LF2000-
WQX and the EC50 values obtained from the literature presented in Table 3 
(Zounkova, Odraska et al. 2007; Zounkova, Kovalova et al. 2010; Brezovšek, Eleršek 
et al. 2014; Franquet-Griell, Gómez-Canela et al. 2015; Lutterbeck, Kern et al. 2015). 
Ecotoxicity data of these drugs are scarce, although short term toxicity in aquatic 
organisms, usually Daphnia magna was available (Franquet-Griell, Gómez-Canela et 
al. 2015). The toxicity endpoints for these drugs was found to be highly variable with 
the EC50 values ranging from 0.13 (5-fluorouracil) to 1795 mg/L (ifosfamide). 
Nonetheless, the RQ values for these drugs turned out to be <<1.0 indicating a very 
low risk with regards to acute toxicity effects to aquatic invertebrates. Imatinib was 
the drug which provided the highest RQ, calculated using the LC50 value of 2.3 mg/L 
for P. Subcapitata toxicity test resulting in the highest RQ of 0.027 in the River Aire 
at approximately 70-75 km downstream from Airton at site A7 (STP-1) and A8 
(downstream of Leeds STP). A predictive study in NE Spain (Catalonia) found 
hydroxycarbamide to have the highest RQ (3.21E-04) for the L01 drugs, calculated 
with an EC50 value >100 mg/L (Franquet-Griell, Gómez-Canela et al. 2015).  
Anticancer drugs are often administered as combinational chemotherapy where a 
mixture of agents are used in a standardised regime and they can therefore be 
expected to be released in mixtures in wastewaters (Booker, Halsall et al. 2014; 
Parrella, Kundi et al. 2014). To determine the cumulative effects the ∑RQ values of 
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all compounds showed low risk in the River Aire (max 0.048) and the River Calder 
(max 0.037). These values are higher than those predicted in Spain (RQ 0.014), which 
was calculated using a worst case scenario and included a list of 25 chemicals, some 
from a different ATC classification (Franquet-Griell, Gómez-Canela et al. 2015). A 
study investigated the synergistic effect of long term exposure to 5-fluorouracil, 
cisplatin, etoposide and imatinib by testing binary mixtures in aquatic organisms (e.g. 
D. magna) and found that mixtures of the anticancer agents gave the same effect as
exposure to a single drug , but at much lower concentrations (Parrella, Lavorgna et al. 
2014). There is a lack of literature regarding the toxicity for complex mixtures of 
anticancer drugs in the environment. The  low concentrations and their ability to 
interact with DNA makes these substances hard to define a ‘safe level’ and more 
sensitive toxicity assays addressing a range of chronic responses should be performed  
including  effects arising due to exposures to mixtures (Parrella, Lavorgna et al. 2014; 
Franquet-Griell, Gómez-Canela et al. 2015).   
Conclusions 
This study presented the occurrence of cyclophosphamide and ifosfamide in a river 
network highly affected by urban and industrial pressures. Cyclophosphamide and 
ifosfamide were detected along the River Aire (UK) at high concentrations, reaching 
6.1 ng/L for CP and 2.2 ng/L for IF. The highest concentration of these contaminants 
was observed near highly populated areas and wastewater discharges which were 
identified as an important source of these contaminants. Comparison of modelled to 
measured river concentrations was for most parts, reasonably predicted by LF2000-
WQX. Underestimations occurred for CP in the River Aire after the major 
conurbation of Leeds, with measured concentrations elevating for the remainder of 
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the river length despite the dilution effect of the two rivers merging.  Overall, the use 
of consumption data is good at predicting river water concentrations for the dissolved 
chemicals, like CP and IF and based on these predictions it should do a reasonable job 
for the ten priority agents in the River Aire and Calder. However, for more reactive 
drugs which show sufficient loss in STPs then LF2000-WQX may not perform as 
well. Where available, measured effluent data should be used to check and refine, if 
necessary, exposure assessments for such chemicals. A risk assessment was 
performed based on water concentration predictions and acute toxicity data. The 
cumulative effects of the sum of RQ values showed no risk of acute toxicity for 
aquatic invertebrates in either the River Aire or Calder. However, long term studies 
for these pollutants in the water environment are needed to define the environmental 
stress produced through the continuous exposure to anticancer drugs in these rivers. 
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Figure 1: Map of sampling locations along the River Aire (A1 to A14) and along the 
River Calder (C1 to C11). STPs are illustrated; the triangle represents sewage works 
that serve a population of <50,000, a pentagon represents STPs with a population 
between 50,000 – 100,000, a circle represents STPs with a population between 
100,000 – 150,000 and a square represents large sewage treatment plants serving a 
population over 150,000. 
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Figure 2: Measured environmental concentrations (MEC) of CP (April 2013 and July 
2013) and predicted environmental concentrations (PEC) of CP along the River Aire, 
Yorkshire (NE England).  PECs were calculated using regional consumption data with 
the assumption that there was no removal during sewage treatment (CP = 0.5 
µg/cap/d). The solid dark line represents the MEC (April 2013), the dashed line 
represents the MEC (July 2013), the dotted line represents the 95th percentile PEC 
values and the shaded area represents the simulated downstream mean flow rate. (a) 
Downstream from Airton (River Aire) (Airton is the first sampling point near the 
upland source of the river) and (b) Downstream from Widdop (River Calder) (Widdop 
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Figure 3: MEC of IF (April 2013 and July 2013) and PEC of IF downstream from 
Airton (River Aire) calculated using regional consumption data with the assumption 
that there was no removal during sewage treatment (IF = 0.5 µg/cap/d). The solid dark 
line represents the MEC (April 2013), the dashed line represents the MEC (July 
2013), the dotted line represents the 95th percentile PEC values and the shaded area 
represents the simulated downstream mean flow rate. 
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